

AD_____

Award Number: DAMD17-94-J-4293

TITLE: Tumor Suppressor Genes in Early Breast Cancer and its Progression

PRINCIPAL INVESTIGATOR: Alison M. Goate, Ph.D.

CONTRACTING ORGANIZATION: Washington University School of Medicine
St. Louis, Missouri 63110

REPORT DATE: September 2000

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 1702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010620 115

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2000	3. REPORT TYPE AND DATES COVERED Final (1 Sep 94 - 31 Aug 00)	
4. TITLE AND SUBTITLE Tumor Suppressor Genes in Early Breast Cancer and its Progression			5. FUNDING NUMBERS DAMD17-94-J-4293	
6. AUTHOR(S) Alison M. Goate, Ph.D.			8. PERFORMING ORGANIZATION REPORT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Washington University School of Medicine St. Louis, Missouri 63110 E-MAIL: goate@icarus.wustl.edu				
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer. From our allelotyping study of DCIS, chromosomal regions of 8p, 13q, 16q, 17p and 17q showed loss of heterozygosity (LOH) significantly above background (5%). We concentrated our efforts on the LOH mapping of a region on 8p (30% LOH) and identified the smallest common deletion region located at 8p22-p23 in an ~1.4 cM interval. An integrated YAC/BAC clone contig covering the deletion region was constructed using CITB and RPCI-11 BAC libraries and the publicly available YAC contig information. STSs (sequence tagged sites) developed from CITB BACs and the publicly available insert end sequences from RPCI-11 BACs on the contig were used for database search. Seven clones with full working draft sequences were identified and localized to the contig. Clone RPCI-11 184O21 contains genomic sequence for the tyrosine kinase, blk. A second predicted gene in the same clone shows 89% homology to hematopoietic cell kinase (Hck), a member of the Src family of tyrosine kinases. Clone RPCI-11589N15 contains sequences homologous to human procathepsin B, Squalene synthase and GATA-4. When the sequence of the entire deletion region becomes available, gene-finding programs can be used to identify all genes in this region and assess the likelihood of a gene being a tumor suppressor gene (TSG). Then, the putative TSGs can be evaluated on normal and tumor tissues of DCIS cases.				
14. SUBJECT TERMS Tumor Suppressor Genes, Atypical Hyperplasia, Ductal Carcinoma In-Situ, Lobular Neoplasia, Progression, Metastasis, Humans, Anatomical Samples, Breast Cancer				15. NUMBER OF PAGES 57
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 9/30/00

PI - Signature Date

Final Report for Grant Number DAMD17-94-J-4293

Tumor Suppressor Genes in Early Breast Cancer and its Progression

Alison M. Goate, D. Phil.

Table of Contents

Front cover	1
SF 298	2
Foreword	3
Table of Contents	4
Introduction	
A. Nature of the problem	5
B. Background	5
Body	
Task 1	6-8
Task 2	8
Task 3	8
Task 4	8-11
Key Research Accomplishments	11-12
Publications resulting from this research project	12
Conclusions	12-13
References	13-16
Appendices	

Introduction

A. Nature of the problem

An increasing percentage of breast cancer is being detected at a pre-invasive stage: ductal carcinoma *in situ* (DCIS). DCIS is a form of breast cancer in which malignant cells have not penetrated the basement membrane.⁽¹⁾ The histopathological diagnosis encompasses a heterogeneous group of subtypes, including comedo, cribriform, solid, papillary and micropapillary, some of which may differ in biological behavior. The potential for associated micro-invasion and the likelihood of recurrence after breast conservation therapy are higher with the comedo subtype.^(2,3) As with invasive breast cancer, DCIS can also be stratified by nuclear grade: high, intermediate, and low. Circumstantial evidence that DCIS is a precursor lesion to invasive ductal carcinoma is based on three observations: the frequent co-existence of DCIS and invasive cancer in the same breast;⁽⁴⁾ the greatly increased risk of subsequent invasive breast cancer in women with biopsy-proven DCIS;⁽⁵⁾ and the finding that when a local recurrence is seen after breast-conserving treatment of DCIS there is a 50% chance that the recurrence will be of the invasive variety.⁽⁶⁾ DCIS is not an obligate precursor however, and other possible pathways to invasion may exist such as the *de novo* transition to malignancy of normal epithelium without an intervening non-invasive stage. For many years the standard treatment for DCIS has been total mastectomy, though lumpectomy with adjuvant radiation is being utilized currently for small, well-localized areas of DCIS.

Lobular carcinoma *in situ* (LCIS), on the other hand, is not thought to be a pre-invasive cancer but rather an indicator of increased risk of breast cancer. Interestingly, the risk is the same in both breasts regardless of the side in which the LCIS was detected. That the LCIS cells do not inevitably progress to invasive breast cancer is evidenced by the fact that, of those cancers which do develop, only half are of the invasive ductal variety.⁽⁷⁾

Atypical lobular hyperplasia (ALH) and atypical ductal hyperplasia (ADH) are considered to be high-risk lesions both associated with an increase of 4-5 fold compared to the general female population. If a strong family history of breast cancer exists, the risk is doubled to 8-9 fold.⁽⁵⁾

Our studies have concentrated on the genetic changes that occur in DCIS and the transition from DCIS to invasive breast cancer. A better understanding of the oncogenesis of breast cancer at the molecular level, and the correlation of this information with clinical data, may aid in treatment choices.

B. Background

Most solid tumors arise due to the inactivation of tumor suppressor genes and activation of oncogenes. The accumulation of genetic changes is believed to result in the invasive followed by the metastatic phenotypes. Loss of heterozygosity (LOH) of one of a pair of alleles in tumor tissue compared to matched normal control from the same individual can reveal areas of chromosomal deletion that are likely to contain putative tumor suppressor genes. A large number of articles have been published on LOH in invasive breast cancer, and virtually every human chromosome has been shown to exhibit allelic loss.^(8,9) The most frequent losses in invasive breast cancer are seen on chromosome 7q,^(8,10,11) 16q,^(8,9,12-14) 17p,^(8,9,15-18) 17q,^(8,9,19-25) and 18q.^(8,22,26,27) Less frequent losses are found on 1p,^(8,9,28) 1q,^(8,9,29,30) 3p,^(8,9,17) 6q,^(8,9) 8p,^(8,16) 11p,^(8,31) and 13q.^(9,17)

Because of the multiple putative tumor suppressor loci that exhibit LOH in invasive

breast cancer, it is not clear which loci are involved in oncogenesis and which are lost randomly due to the instability conferred by the malignant state of the genome.

Allelotyping involves the comprehensive screen of the genome for LOH in a particular cancer. Generally an initial screen will involve assaying with at least one marker from each non-acrocentric chromosomal arm, thereby the average or baseline level of LOH can be determined. This may vary from 5 to 20% depending on the type of cancer. A significant level of LOH at a single locus, indicating the site of possible tumor suppressor genes involved in oncogenesis, can be ascertained once the background level is known. Regions that show significant LOH can then be analyzed with additional markers to refine the smallest deleted region that may contain the tumor suppressor gene. The analysis of tumors with a number of markers also permits calculation of the fractional allelic loss (FAL) for each tumor. This has been defined as the total number of chromosomal arms which show LOH divided by the total number of informative arms for that tumor.^(32,33) FAL has been correlated with patient outcome in colon cancer,⁽³²⁾ and may correlate with clinical information in other tumor types.

Few reports exist on the molecular changes in DCIS that pertain to invasive breast cancer. Davidoff et al.⁽³⁴⁾ studied 6 examples of synchronous DCIS and invasive cancer for expression of p53 and found the same levels of protein expression in each tissue type. Expression of the oncogenes c-erbB-2 and c-myc is also consistent between coexisting pre-invasive and invasive breast cancer.^(35,36) Zhuang et al. studied allelic loss for two loci on 11q13 (INT2 and PYGM). They found that for every case of DCIS which showed LOH (N=15), loss of the same allele was seen in the corresponding invasive tumor.⁽³⁷⁾ O'Connell et al.⁽³⁸⁾ studied four loci TPO (2pter), D4S192 (4q25-34), D16S265 (16q21) and D17S579 (17q21) and found that 8 of 10 cases of DCIS shared LOH patterns with more advanced lesions for at least one of the 4 loci.

Body:

Task 1. The identification and characterization of the extent of chromosomal deletion in DCIS.

Materials and Methods

Study subjects

As described in previous progress reports, paraffin embedded samples of DCIS were collected from several hospitals in St. Louis (Barnes-Jewish, Deaconess Central, St. Louis University, and the Outpatient Surgery Center). Subtypes of DCIS and nuclear grade of the tumor were classified by the pathologists. Either matched archival normal lymph node DNA or leukocyte DNA was used as a control. When it was necessary to draw blood for a normal control, informed consent was obtained following Institutional Review Board approval. Samples were microdissected to enrich for tumor cells and DNA was purified as previously described.⁽³⁹⁾ After microdissection, tissue samples containing an insufficient number of tumor cells for the normal DNA extraction procedure were digested in small volumes (10-20 μ l) of lysis buffer containing proteinase K, then phenol and chloroform extracted once before sodium acetate/ethanol precipitation.

LOH analysis

We have used a panel of highly polymorphic microsatellite markers for LOH assay. DNA extracted from the tissues was resuspended in water and then aliquots were used

directly as a template (5-10 ng) for PCR amplification. Initial PCR conditions were obtained via the Genome Data Base (GDB, <http://gdbwww.gdb.org>) and then optimized in the laboratory. PCR was performed in the tumor/normal pairs and products were separated on denaturing polyacrylamide sequencing gels. LOH was determined by a combination of visual inspection and scanning densitometry of the autoradiographs. A 2.5 fold difference in the relative allele intensity ratios between an informative tumor/normal pair was scored as LOH (allele1/allele2 in tumor compared to allele1/allele2 in normal). To maintain a conservative scoring approach, marginal allele reduction by inspection was not scored as LOH. Tumor samples with equivocal results were re-dissected in an attempt to obtain a "purer" specimen and the experiments were repeated. All LOH designations were scored by two independent scientists and repeated to verify the result.

Genetic Linkage Maps

Once a region of chromosomal deletion has been identified it can be narrowed down using a panel of closely linked markers which map to that area. Since new microsatellite markers appeared in the public databases daily, they did not appear on published genetic maps. In order to determine the deletion map in the tumors, it is necessary to know the precise location of the markers being used. A fine genetic linkage map was constructed using genotypic data from a number of families generated in the lab and publicly available data (<http://www.cephb.fr/cephdb/>) of Centre d'Etude Polymorphisme Humaine (CEPH) reference families. Merged genotypic data were processed using the linkage program CRIMAP (P. Green, unpublished) with minimum odds for order of 1000:1. Having identified a small region of deletion (preferably no larger than 1cM) positional cloning techniques can be undertaken to clone the putative tumor suppressor gene contained within the region.

Results & Discussion

During the first year of this project we completed the allelotyping of DCIS. A total of 61 samples of DCIS were assayed. The average number of informative tumors examined for each marker was 19 (range 8 to 48). The median fractional allelic loss (FAL) was 0.037. The highest % of LOH was shown for loci on 8p (18.7%), 13q (18%), 16q (28.6%), 17p (37.5%) and 17q (15.9%). LOH on 18q was found in 10.7% of informative tumors. FAL was associated with LOH on 17p with high nuclear grade and with the comedo subtype of DCIS. LOH on 17p correlated with LOH on 17q and on 13q. Additional markers were employed for 16q and 17p to determine the smallest common region of deletion and maps of 17p and 16q were generated.⁽⁴⁰⁾ Aldaz et al. also studied allelic loss in a total of 23 examples of DCIS. They found the most frequent sites of loss to be on chromosomes 7p, 16q, 17p and 17q.⁽⁴¹⁾

During the second year of the project we concentrated our efforts on the refinement of the area of loss on 8p. In a more detailed analysis of LOH on 8p we genotyped 18 polymorphic markers in 65 sporadic DCIS cases and observed LOH in 29% of informative samples.⁽⁴²⁾ Several investigators have reported two distinct regions of loss on 8p in breast cancer, located at 8p21 and 8p22. Yaremko et al. studied 20 examples of invasive ductal cancer and found the overall rate of LOH on 8p to be 55% with loss at 8p22 observed more frequently than at 8p21.⁽⁴³⁾ Recently, Yokota et al. reported allelic loss in two regions (8p12-21 and 8p22-23.1 encompassing D8S549 and D8S1992) in advanced tumors, implying that allelic loss on 8p may contribute to the progression of breast carcinoma.⁽⁴⁴⁾

Simultaneously with LOH analysis, we have generated a meiotic linkage map for 8p to resolve previously reported conflicting map orders from the literature. The map spanned from the telomere of 8p to just beyond the centromere with a distance of 80.8 cM. The average distance between markers is 3.5 cM. Our genetic mapping study refined the deleted region to a 1.4 cM interval between markers D8S520 and D8S265.⁽⁴⁵⁾ Anbazhagan et al. found the most common region of loss in 60 invasive ductal breast tumors to be at 8p21.3-p23.3 between D8S560 and D8S518.⁽⁴⁵⁾ The 1.4 cM region of loss we have identified lies within this region.

Task 2. The study of chromosomal deletions in hyperproliferative breast conditions.

We assayed 3 pairs of LCIS/normal samples using several markers on 8p. No LOH was observed.

Task 3. The study of chromosomal deletions in the progression of DCIS to invasive and metastatic phenotypes.

To study genetic changes and the evolution of breast cancer we have assayed for loss of heterozygosity (LOH) in twelve sets of synchronous carcinoma *in situ* (CIS) and invasive cancer, compared to normal control DNA. Microsatellite markers were used which map to each non-acrocentric autosomal arm. Eight tumor sets demonstrated LOH of the same allele in both concurrent invasive cancer and DCIS, for a total of eighteen chromosomal loci. Three of nine tumor sets showed LOH on 11p. In two of these sets LOH was seen on 11p only in the invasive tumor, not the corresponding CIS. One of these tumors also exhibited allelic loss in the invasive tumor for 4 loci, all of which were retained in the non-invasive tumor. For two tumor sets LOH was mirrored in matched DCIS, invasive tumor and lymph node metastases. The maintenance of LOH for certain loci throughout the stages of breast cancer suggests clonality of the cancer cells. Tumor suppressor loci on 11p may be involved in the invasive phenotype.⁽⁴⁷⁾

Task 4. Cloning a tumor suppressor gene involved in breast cancer.

Materials and Methods

Radiation hybrid maps

As described in previous progress reports, G3 and GB4 are the two radiation hybrid mapping panels (Research Genetics, Inc. Huntsville, AL) we used to construct the RH placement map. The G3 panel, comprised of 83 RH clones from the whole human genome, was created at the Stanford Human Genome Center and is considered a medium resolution panel (i.e. 500 Kb resolution). The GB4 panel, comprised of 93 RH clones from the whole human genome, has lower resolution (i.e. 1000 Kb). STS markers were assayed by PCR amplification and sized on 3% agarose gels stained with ethidium bromide. Each assay was performed twice, i.e. PCR products at the expected size were observed on each of the duplicate gels in order to be scored as positive. Data generated from the GB4 panel were submitted to the Whitehead Institute Center for Genome Research (WICGR) Mapping Service Center. Data generated using the G3 panel were submitted to the Stanford RH server. A list of the most tightly-linked mapped markers, the LOD score between the linked markers, and the distance in cR between the submitted marker and the linked marker on the map reported from the servers were used as a reference for the framework. We then used the program RHMAP, version 3.0 (<http://www.sph.umich.edu/group/statgen/software>)⁽⁴⁸⁾ to

integrate our RH data from the six markers covering the deletion region into the framework map.⁽⁴⁵⁾

YAC and BAC clone contig construction

The CEPH YAC contig WC-1195 from WICGR was used for the initial contig construction. YAC clones used in the mapping were propagated on YPD medium plates. Ten isolated colonies from each YAC clone were tested using a "whole cell PCR" assay to identify colonies positive for marker(s) from the region. For "whole cell PCR", a small amount of an isolated colony was suspended in 5 µl of deionized water and the suspension was used directly as the template in a standard PCR reaction. The standard ligation-mediated PCR method was used to develop new STSs from YACs.

For BAC contig construction, we screened the human BAC library CITB-978SK-B & CITB-HSP-C, constructed by the California Institute of Technology (obtained from Research Genetics, Inc., Huntsville, AL). The library screen involved a total of 120 PCR reactions for each STS assay. As with YAC clone isolation, each identified BAC clone was then verified by a "whole cell PCR" assay, using 10 randomly selected colonies as candidates. After the positive BAC clones were verified, single BAC colonies were propagated in liquid medium, cells harvested, and insert DNA prepared using the Plasmid Midi-Kit from Qiagen Inc. (Chatsworth, CA). Each BAC clone was partially sequenced on an ABI 373 DNA sequencer (PE/ABI), from the insert ends using modified T7 and Sp6 primers. The sequence generated was analyzed for candidate PCR primer sequences using the program PRIMER 0.5 (Lincoln and Lander, MIT Center for Genome Research). STSs developed from BACs were tested using the NIGMS (#2) rodent/human hybrid panel, in which each hybrid cell contains a single human chromosome, and only chromosome 8 specific STSs were used as entry points for chromosome walking.

The insert sizes of BAC clones were determined by digesting clones with Not I and restriction fragments were separated on 1% agarose gels in 0.5X TBE buffer using MidRange II PFG markers (NE BioLabs) as size standards. Gels were electrophoresed at 6 V/cm with an initial pulse of 5 seconds and a final pulse of 15 seconds for 18 hrs at 14 C in a BioRad CHEF-DR II apparatus.

Colony Hybridization

To effectively sequence the deletion region with the high-throughput technique at the Genome Sequencing Center of Washington University, a second BAC library (RPCI-11) was screened using hybridization and fingerprinting. We used end sequences derived from CITB-978SK-B and CITB-HSP-C BAC clones to generate 23 overgos using the techniques described in Current Protocols in Human Genetics. Briefly, two 24-mer oligonucleotides with an overlap of 8 bp are designed from the target sequence and then annealed to create two 16-bp overhangs. Klenow fragment with incorporated radionucleotides is used to fill in the 16-bp overhangs to generate a double-stranded 40-mer probe with high specific activity. These overgo probes were pooled and hybridized to nylon filters containing immobilized DNA from the RPCI-11 BAC library (Research Genetics, Inc., Huntsville, AL). After hybridization, the filter was washed to remove non-specifically bound probe and visualized by autoradiography.

Fingerprinting

Two colonies for each positive BAC clone from the hybridization screening were isolated and propagated in liquid YT medium containing chloramphenicol. A modified alkaline lysis procedure^(49,50) was followed for DNA preparation. Samples were digested with restriction endonuclease Hind III and electrophoresed on 1% SeaKem LE (FMC BioProducts) agarose gels. After electrophoresis, gels were stained with 1:10,000 dilution of SYBR Green (FMC BioProducts) and then imaged using a Molecular Dynamics FluorImager SI. Fingerprinting data were collected as the distance that restriction fragments migrate on an agarose gel relative to fragments in the standard marker (Boehringer-Mannheim marker V in our study) lane using the program FPC version 3.2^(49,51) (<http://www.sanger.ac.uk>). The relative mobilities of restriction fragments from newly isolated RPCI clones were compared with the fingerprinting data of CITB clones to assemble the comprehensive sequence-ready contig.

Identification of tumor suppressor gene candidates

First, the TIGR BAC database was searched to identify insert end sequences of incorporated RPCI-11 BAC clones identified from the fingerprinting. Then, the end sequences of RPCI-11 BACs identified from the database and those we developed from the CITB BACs were used to screen publicly available nucleotide databases of fully sequenced clones using the program BLAST (<http://www.ncbi.nlm.nih.gov>).

Identified clones with full sequences at the working draft stage were examined with the dbEST, UniGene databases (<http://www.ncbi.nlm.nih.gov>) and the program GENSCAN (<http://ccr-081.mit.edu/GENSCAN.html>) to detect known genes and possible exons. Finally, publicly available protein databases (<http://www.ncbi.nlm.nih.gov>) were used to search for homologies between predicted peptides and known genes.

Results & Discussion

We have constructed a radiation hybrid map for the 1.4 cM deletion interval between markers D8S520 and D8S265 within chromosome 8p22-p23.⁽⁴⁵⁾ This map provides an independent means of ordering the markers in this region and helped to verify the linkage map marker order, a necessary step prior to the construction of a clone contig and gene identification. The distance of 42.3 cR, or approximately 1,565 kb (assuming 37 kb per cR)⁽⁵²⁾ between the markers D8S265 and D8S520 confirmed the approximate size of 1.4 cM deletion region from our genetic mapping result.

After we confirmed the genetic marker orders with RH mapping, an integrated YAC/BAC clone contig covering the ~1.4 cM LOH interval near D8S550 was constructed.⁽⁴⁴⁾ This contig spanning ~1730 kb consists of 13 YACs and 27 CITB BACs. Eleven ESTs localized to the region near D8S550 were mapped to our contig. Two of these 11 ESTs, N29512 and AA018590, identified by the marker SGC30677 in UniGene, were developed from a cDNA clone with sequence homology to human Farnesyl Diphosphate Farnesyltransferase. EST H16027, which is one of the ESTs detected by the marker WI-8953, is derived from a cDNA clone with homology to human procathepsin B.

Since only 11 ESTs were mapped to the contig, most of which gave no clue to their function, we decided to use a sequencing approach for the TSG candidate search. As described in previous progress reports, our collaboration with the Genome Sequencing Center of Washington University has increased the depth of the contig. A total of 57

clones from the second BAC library (RPCI-11) screening were isolated and incorporated into a refined sequence-ready contig by hybridization and fingerprinting. The BACs are now being sequenced.

During the last project year, we have focused on DNA sequence analyses. The STSs we developed from CITB BACs and the publicly available insert end sequences of RPCI-11 BACs were used to search the public databases with the program BLAST. Seven clones with full working draft sequences were identified and localized to the contig by electronic PCR using STS assays (Figure. 1). A total of 13 STSs were localized to clone RPCI-11 177H2 and the overlapping clone RRPCI-11 184L12. Although many exon fragments were detected in these two clones and the other overlapping clone RPCI-11 44D1 using GENSCAN, there are currently no corresponding full length cDNAs in the public databases.

Six STSs and one EST (WI-6800) were localized to clone RPCI-11 110L10 (Figure 1) by homology search to the htg database. One gene predicted by the GENSCAN program was also identified and localized to this clone by homology to a Unigene cluster (gi=7020537). The function of this gene remains unknown. Two additional genes are predicted by GENSCAN. Full length cDNAs for these genes do not currently exist in the public databases, however, ESTs corresponding to exon fragments are detected (Figures 1 & 2).

Fourteen STSs, one EST (AA504989) and two microsatellite markers (D8S1695 and D8S1759) were placed on clone RPCI-11 148O21 (Figure 1). Two genes were detected in this clone by homology to the Unigene database and by the GENSCAN program. One of these two predicted genes shows 89% homology with amino acids 369-531 of hematopoietic cell kinase (Hck), a member of the Src family of tyrosine kinases. The other putative gene shows >97% homology to a protein tyrosine kinase (blk) (Figure 3).

Three STSs and 5 ESTs (R01183, R01769, H16027, Z45810 and N29512) were placed on clone RPCI-11 589N15 (Figures 1). Three known genes, squalene synthase, human procathepsin B and GATA-4 map within this clone. However, this clone currently exists as 33 discontinuous fragments. It is clear from figure 4 that they are not yet in the correct order since exons for squalene synthase are randomly distributed throughout the clone. The large number of fragments makes the GENSCAN predictions less meaningful since we cannot predict which exons belong to which gene except for those with clear homology to known genes.

Key research accomplishments

- Chromosomal deletions on 8p, 13q, 16q, 17p, and 17q were observed from our initial alleotyping study of DCIS.
- Our LOH assay of LCIS suggested that tumor suppressor loci on 11p may be involved in the invasive phenotype.
- Our data identified the smallest common LOH region of DCIS to be located at 8p22-p23.
- The smallest deletion region of ~1.4 cM has been determined and confirmed by meiotic linkage and radiation hybrid mapping.

- We constructed a ~1.7-Mb sequence-ready YAC/BAC contig covering the deletion region that may contain a tumor suppressor gene.
- Based on the currently available databases, 7 clones with full working draft sequences were identified using the information and clones on the physical map.
- Clone RP11-148O21 contains two putative tyrosine kinases. The blk gene, which has previously been mapped to 8p22-p23, is within this clone. A second polypeptide of 601 amino acids that is predicted by GENSCAN shows 89% homology to hematopoietic cell kinase (Hck) between aa369 and aa531 of the hypothetical gene sequence. Hck is a member of the Src family of tyrosine kinases.
- Clone RP11-589N15 that maps to the proximal end of the contig contains sequences homology to human procathepsin, squalene synthase and GATA-4.

Publications resulting from this research project

1. Wang, J.C., Radford, D., Wylie C., McPherson, J., Donis-Keller, H., Goate, A.. Physical mapping and identification of tumor suppressor gene candidates involved in ductal carcinoma in situ on chromosome 8p22-p23. The 200Era of Hope Proceedings, Volume 1, p151.
2. Wang, J.C., Radford, D., Holt, M., Helms, C., Goate, A., Brandt, W, Parik, M., Phillips, N.J., DeSchryver, K., Schuh, M.E., Fair, K.L., Ritter, J.H., Marshall, P., and Donis-Keller, H. (1999). Sequence-ready contig for the 1.4 cM ductal carcinoma *in situ* loss of heterozygosity region on Chromosome 8p22-23. Genomics, 60:1-11.
3. Wang, J.C., Radford, D., Holt, M., Helms, C., Brandt, W., and Donis-Keller, H. (1997). Chromosome 8p deletions in ductal carcinoma *in situ* (DCIS) of the breast. Am J Hum Genet S61:A87.
4. Radford, D.M., Fair, K.L., Phillips, N. J., Ritter, J.H., Steinbrueck, T., Holt, M.S. and Donis-Keller, H. (1995). Allelotyping of ductal carcinoma *in situ* (DCIS) of the breast; deletion of loci on 8p,13q,16q,17p and 17q. Cancer Res. 55:3399-3405.
5. Radford, D.M., Holt, M.S., Phillips, N.J., Fair, K.L., Ritter, J.H., and Donis-Keller H. (1995). Allelic loss on chromosome 8p occurs early in the development of breast carcinoma. Surgical Forum, XLVI: 533-5.
6. Radford, D.M., Phillips, N.J., Fair, K.L., Ritter, J.H., Holt, M., and Donis-Keller, H. (1995). Allelic loss and the progression of breast cancer. Cancer Res. 55:5180-5183
7. Radford, D.M., Fair, K.L., Thompson, A.M., Ritter, J.H., Holt, M., Steinbrueck, T., Wallace, M., Wells, S.A. and Donis-Keller, H.R. (1993). Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. Cancer Res. 53:2947-2950.
8. Radford, D.M., Fair, K.L., Thompson, A.M., Ritter, J.H., Holt, M., Wells, S.A.Jr., Donis-Keller, H.R. (1993). Chromosomal regions implicated in the development of breast cancer. Surgical Forum XLIV: 502-504.

Conclusion

From our initial allelotyping study of DCIS we determined that the background rate of loss of heterozygosity (LOH) is low (5%). The chromosomal regions showing LOH significantly above background were 8p, 13q, 16q, 17p and 17q. In our study of 65 cases of DCIS, using 18 markers on 8p and one on 8q, LOH was seen on 8p in 29% of informative cases. Our genetic linkage analysis and RH mapping effort localized the smallest deletion region to 8p22-p23 in an approximately 1.4 cM interval between D8S265 and D8S520. We also constructed an integrated YAC/BAC clone contig

covering this deletion region. The STS information and the overlapping BAC clones on the contig provided the starting material for large scale sequencing of this genomic region. To date, 7 BAC clones with full sequence at the working draft stage have been identified in the databases. A total of ~175 exons were predicted from these clones using the program GENSCAN. In addition, five genes were detected in two clones, RP11-148O21 and RP11-589N15.

When the sequencing for the entire deletion region becomes publicly available, gene-finding programs can be used to identify all genes in this region and assess the likelihood of a gene being a tumor suppressor gene. Then, the putative TSGs can be evaluated on normal and tumor tissues of DCIS cases.

References

1. Broders A.C. Carcinoma *in situ* contrasted with benign penetrating epithelium. JAMA 99:1670-1674, 1932.
2. Lagios M.D. Duct carcinoma *in situ*. In: Breast Cancer: Strategies for the 1990s. Surg. Clin. N. Am. 70:853-871, 1990.
3. Schnitt S.J., Silen W., Sadowsky N.L., Connolly J.L. and Harris J.R. Ductal carcinoma *in situ* (intraductal carcinoma) of the breast. New Engl. J. Med. 318:898-903, 1988.
4. Alpers C.E. and Wellings S.R. The prevalence of carcinoma *in situ* in normal and cancer-associated breasts. Human Pathol. 16:796-807, 1985.
5. Dupont W.E. and Page D.L. Risk factors for breast cancer in women with proliferative breast disease. New Engl. J. Med. 312:146-151, 1985.
6. Solin L.J., Recht A., Fourquet A., Kurtz J., Kuske R., McNeese M., McCormick B., Cross M.A., Schultz D.J., Bornstein B.A., Spitalier J.-M., Vilcoq J.R., Fowble B.I., Harris J.R. and Goodman R.L. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma *in situ*) of the breast. Cancer 68:2337-2344, 1991.
7. Gump F.E. Lobular carcinoma *in situ*: pathology and treatment. Surg. Clin. N. Am. 70:873-883, 1990.
8. Devilee P., van Vliet M., van Sloun P., Kuipers-Dijkshoorn N., Hermans J., Pearson P.L. and Cornelise C.J. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene 6: 1705-1711, 1991.
9. Sato T., Tanigami A., Yamakawa K., Akiyama F., Kasumi F., Sakamoto G. and Nakamura Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 50:7184-7189, 1990.
10. Zenklusen J.C., Bieche I., Lidereau R. and Conti C.J. (C-A)_n microsatellite repeat D7s522 is the most commonly deleted region in human primary breast cancer Proc. Natl. Acad. Sci. USA 91:12155-12158, 1994.
11. Bieche I., Champene M.H., Matifas F., Hacene K., Callahan R. and Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 339:139-143, 1992.
12. Lindblom A., Rotstein S., Skoog L., Nordenskjold M. and Larsson C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res. 53:3707-3711, 1993.
13. Cleton-Jansen A., Moerland E.W., Kuipers-Dijkshoorn N.J., Callen D.F., Sutherland G.R., Hansen B., Devilee P. and Cornelisse C.J. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes and Cancer 9:101-107, 1994.
14. Tsuda H., Callen D.F., Fukutomi Y., Nakamura Y. and Hirohashi S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespective of differences in phenotype and extent of spread. Cancer Res. 54:513-517, 1994.

15. Lindblom A., Skoog L., Andersen T.I., Rotstein S., Nordenskjold M. and Larsson C. Four separate regions on chromosome 17 show loss of heterozygosity in familial breast cancers. *Hum. Genet.* 91:6-12, 1993.
16. Lindblom A., Skoog L., Rotstein S., Werelius B., Larsson C. and Nordenskjold M. Loss of heterozygosity in familial breast carcinomas. *Cancer Res.* 53:4356-4361, 1993.
17. Andersen T.I., Gaustad A., Ottestad L., Farrants G., Nesland J.M., Tveit K. and Borrensens A.L. Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17p and 17q in human breast carcinomas. *Genes Chromosomes and Cancer* 4:113-121, 1992.
18. Sato T., Akiyama F., Sakamoto G., Kasumi F. and Nakamura Y. Accumulation of genetic alterations and progression of primary breast cancer. *Cancer Res.* 51: 5794-5799, 1991.
19. Cropp C.S., Champeme M., Lidereau R. and Callahan R. Identification of three regions on chromosome 17q in primary human breast cancer which are frequently deleted. *Cancer Res.* 53: 5617-5619, 1993.
20. Cropp C.S., Lidereau R., Leone A., Liscia D. and Cappa A.P. NME1 protein expression and loss of heterozygosity in primary human breast tumors. *J. Natl. Cancer Inst.* 86:1167-9, 1994.
21. Caligo M.A., Ghimenti C., and Bevilacqua G. NM23.H1 loss of heterozygosity in human mammary carcinomas. *Ann. N.Y. Acad. Sci.* 698:136-142, 1993.
22. Cropp C., Lidereau R., Campbell G., Champene H. and Callahan R. Loss of heterozygosity on chromosomes 17 and 18 in breast carcinoma: Two additional regions identified *Proc. Natl. Acad. USA* 87; 7737-7741, 1990.
23. Saito H., Inazawa J., Saito S., Kasumi F., Koi S., Sagae S., Kudo R., Saito J., Noda K. and Nakamura Y. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. *Cancer Res.* 53: 3382-3385, 1993.
24. Borg A., Zhang Q., Johannsson O. and Olsson H. High frequency of allelic imbalance at the BRCA 1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. *J. Natl. Cancer Inst.* 86:792-794, 1994.
25. Futreal P.A., Soderkvist P., Marks J.R., Iglehart J.D., Cochran C., Barrett J.C. and Wiseman R.W. Detection of frequent allelic loss on proximal 17q in sporadic breast carcinoma using microsatellite length polymorphisms. *Cancer Res* 52; 2624-27, 1992
26. Thompson A.M., Morris R.G., Wallace M., Wylie A.H., Steel C.M. and Carter D.C. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. *Br. J. Cancer* 68:64-68, 1993.
27. Devilee P., van Vliet M., Kuipers-Dijkshoorn N., Pearson P.L. and Cornelisse C.J. Somatic genetic changes on chromosome 18 in breast carcinomas: is the DCC gene involved? *Oncogene* 6:311-5, 1991.
28. Bieche I., Champene M.-H., Matifas F., Cropp C., Callahan R. and Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. *Cancer Res.* 53: 1990-1994, 1993
29. Chen L., Kurisu W., Ljung B., Goldman E.S., Moore D. and Smith H.S. Heterogeneity for allelic loss in human breast cancer. *J. Natl. Cancer Inst.* 84: 506-510, 1992.
30. Chen L.-C., Dollbaum C. and Smith H.S. Loss of heterozygosity on chromosome 1q in human breast cancer *Proc. Natl. Acad. Sci. USA* 86:7204-7207, 1989
31. Deng G., Chen I.-C., Schott D.R., Thor A., Bhargava V., Ljung B., Chew K. and Smith H.S. Loss of heterozygosity and p53 mutations in breast cancer. *Cancer Res.* 54: 499-505, 1994.
32. Vogelstein B., Fearon E.R., and Kern S.E. Allelotype of colorectal carcinomas. *Science* 244: 217-221, 1989.

33. Kern S.E., Fearon E.R., Tersmette K.W.F., Enterline J.P., Leppert M., Nakamura Y., White R., Vogelstein B. and Hamilton S.R. Allelic loss in colorectal carcinoma. *JAMA* 261:3099-3103, 1989.
34. Davidoff A.M., Kerns B., Iglehart J.D. and Marks J.R. Maintenance of p53 alterations throughout breast cancer progression *Cancer Res.* 51: 2605-2610, 1991.
35. Maguire H.C. Jr., Hellman M.E., Greene M.I. and Yeh I. Expression of c-erbB-2 in *in situ* and in adjacent invasive ductal adenocarcinoma of the female breast. *Pathobiology* 60:117-121, 1992.
36. Watson P.H., Safneck J.R., Le K., Dubik D. and Shiu R.P. Relationship of c-myc amplification to progression of breast cancer from *in situ* to invasive tumor and metastasis. *J Natl. Cancer Inst.* 85: 902-907, 1993.
37. Zhuang Z., Merino M.J., Chuaqui R., Liotta L. and Emmert-Buck M.R. Identical allelic loss on chromosome 11q13 in microdissected *in situ* and invasive breast cancer. *Cancer Res.* 55: 467-471, 1995.
38. O'Connell P., Pekkel V., Fuqua S., Osborne C.K. and Allred D.C. Molecular genetic studies of early breast cancer evolution. *Breast Cancer Res. and Treat.* 32: 5-12, 1994.
39. Radford D.M., Fair K., Thompson A.M., Ritter J.H., Holt M., Steinbrueck T., Wallace M., Wells S.A. and Donis-Keller H.R. Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res.* 53:2947-2950, 1993.
40. Radford D.M., Fair K.L., Phillips N.J., Ritter J.H., Steinbrueck T., Holt M.S. and Donis-Keller H. Allelotyping of ductal carcinoma *in situ* (DCIS) of the breast; deletion of loci on 8p,13q,16q,17p and 17q. *Cancer Res.* 55:3399-3405, 1995.
41. Aldaz C.M., Chen T., Sahin A., Cunningham J. and Bondy M. Comparative allelotype of *in situ* and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res.* 55:3976-81, 1995.
42. Radford D.M., Holt M.S., Ritter J.H., Phillips N.J., Fair K.L., DeSchryver K., Schuh M.E. and Donis-Keller H.R. Allelic loss on chromosome 8p occurs early in the development of breast carcinoma. *Surgical Forum XLVI*: 533-5, 1995.
43. Yaremko M.L., Recant W.M. and Westbrook C.A. Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. *Genes, Chromosomes and Cancer* 13:186-191, 1995.
44. Yokota T., Toshimoto M., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y. and Emi M. Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1 -cM interval of 8p22-p23.1. *Cancer* 85: 447-452, 1999.
45. Wang J.C., Radford D.M., Holt M.S., Helms C., Goate A., Brandt W., Parikh M., Phillips N.J., DeSchryver K., Schuh M.E., Fair K.L., Ritter J.H., Marshall P. and Donis-Keller H. Sequence ready contig for the 1.4 cM ductal carcinoma *in situ* LOH region on chromosome 8p22-p23. *Genomics* 60: 1-11, 1999.
46. Anbazhagan R., Fujii H. and Gabrielson E. Allelic loss of chromosomal arm 8p in breast cancer progression. *Am. J. Pathol.* 152: 815-819, 1998.
47. Radford D.M., Phillips N.J., Fair K.L., Ritter J.H., Holt M.S., and Donis-Keller H. Allelic loss and the progression of breast cancer. *Cancer Res.* 55: 5180-3, 1995.
48. Lunetta K., Boehnke M., Lange K., and Cox D.R. Selected locus and multiple panel models for radiation hybrid mapping. *Am. J. Hum. Genet.* 59: 717-725, 1996.
49. Marra M.A., Kucaba T.A., Dietrich N.L., Green E.D., Brownstein B., Wilson R.K., McDonald K.M., Hillier L.W., McPherson J.D., Waterston R.H. High throughput fingerprint analysis of large-insert clones. *Genomic Res.* 7: 1072-1084, 1997.
50. Sambrook J., Fritsch E.F., and Maniatis T. *Molecular cloning: A laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 1989.
51. Marra M., Kucaba T., Sekhon M., Hillier L., Martienssen R., Chinwalla A., Crockett J., Fedele J., Grover H., Gund C., McCombie W.R. McDonald K., McPherson J.,

- Mudd N., Parnell L., Schein J., Seim R., Shelby P., Waterston R., Wilson R. zA map for sequence analysis of the *Arabidopsis thaliana* genome. *Nat. Genet.* 22: 265-270, 1999.
52. Stewart E.A., McKusick K.B., Aggarwal A., Bajorek E., Brady S., Chu A., Fang N., Hadley D., Harris M., Hussain S., Lee R., Mararukulam A., O'Connor K., Perkins S., Piercy M., Qin F., Reif T., Sanders C., She X., Sun W.L., Tabar P., Voyticky S., Coeles S., Fan J.B., Mader C., Quackenbush J., Myers R.M. and Cox D.R. An STS-based radiation hybrid map of the human genome. *Genome Res.* 7: 422-433, 1997.

Appendix I.

Figure 1. An integrated YAC/BAC clone contig spanning the 1.4cM deletion region

Figure 2. Predicted putative genes in clone RPCI-11 110L10.

Figure 3. Predicted putative genes in clone RPCI-11 148O21.

Figure 4. Predicted putative genes in clone RPCI-11 589N15.




Figure 1. An integrated YAC/BAC clone contig spanning the 1.4-cM deletion region (modified from figure 3 in Genomics 60:1-11). This figure only shows the clones that form the minimal tiling path.

Figure 2. Predicted putative genes in clone RPCI-11 110L10.




Figure 2. Clone RPCI-11 110L10

I. Genes predicted by GENSCAN and by homology to the Unigene database.

FEATURES	Location/Qualifiers
exon	complement(31913..32180) /note="putative exon 1 of cDNA gi=7020537"
exon	complement(49076..49226) /note="putative exon 2 of cDNA gi=7020537"
exon	complement(8146..8282) /note="putative exon 3 of cDNA gi=7020537"
exon	126355..126546 /note="putative exon 4 of cDNA gi=7020537"
exon	127715..127980 /note="putative exon 5 of cDNA gi=7020537"
exon	131046..131225 /note="putative exon 6 of cDNA gi=7020537"
exon	136445..136590 /note="putative exon 7 of cDNA gi=7020537"
exon	138199..138456 /note="putative exon 8 of cDNA gi=7020537"
exon	141214..141375 /note="putative exon 9 of cDNA gi=7020537"
exon	144075..145232 /note="putative exon 10 of cDNA gi=7020537"
CDS	complement(145740..146043) /note="EST marker WI-6800"
misc_feature	79763..92911 /note="assembly_fragment clone_end:SP6 vector_side:left"

Figure 2. Clone RPCI-11 110L10

II. Genes predicted by GENSCAN only.

FEATURES	Location/Qualifiers
promoter	complement(109688..109727) /note="putative promoter of unknown gene #1"
exon	complement(107656..107818) /note="putative exon 1 of unknown gene #1"
exon	complement(107384..107556) /note="putative exon 2 of unknown gene #1"
exon	complement(105399..105504) /note="putative exon 3 of unknown gene #1"
exon	complement(104204..104473) /note="putative exon 4 of unknown gene #1"
exon	complement(103471..103610) /note="putative exon 5 of unknown gene #1"
polyA_signal	complement(88650..88655) /note="polyA site of unknown gene #1"
promoter	146854..146893 /note="putative promoter of unknown gene #2"
exon	152752..153653 /note="putative exon 1 of unknown gene #2"
exon	158221..158313 /note="putative exon 2 of unknown gene #2"
exon	159955..160055 /note="putative exon 3 of unknown gene #2"
exon	161173..161277 /note="putative exon 4 of unknown gene #2"
exon	163185..163321 /note="putative exon 5 of unknown gene #2"
polyA_signal	163891..163896 /note="polyA site of unknown gene #2"

Figure 3. Predicted putative genes in clone RPCI-11 148O21




Figure 3. Putative genes in clone RPCI-11 148021

I. Genes predicted by GENSCAN and by homology to the Unigene database.

FEATURES	Location/Qualifiers
exon	complement(5000..5152) /note="blk=protein tyrosine kinase exon 1"
exon	74962..75057 /note="blk=protein tyrosine kinase exon 2"
exon	75955..76060 /note="blk=protein tyrosine kinase exon 3"
exon	77089..77196 /note="blk=protein tyrosine kinase exon 4"
exon	82253..82422 /note="blk=protein tyrosine kinase exon 5"
exon	83589..83776 /note="blk=protein tyrosine kinase exon 6"
exon	84892..84980 /note="blk=protein tyrosine kinase exon 7"
exon	151219..151383 /note="blk=protein tyrosine kinase exon 8"
exon	152902..153074 /note="blk=protein tyrosine kinase exon 9"
exon	153814..154216 /note="blk=protein tyrosine kinase exon 10"
exon	154303..154529 /note="blk=protein tyrosine kinase exon 11"
polyA_signal	154509..154514 /note="polyA site of blk=protein tyrosine kinase"
exon	75786..75887 /note="tyrosine kinase Hck exon 1"
exon	76920..77027 /note="tyrosine kinase Hck exon 2"
exon	81504..81636 /note="tyrosine kinase Hck exon 3"
exon	82153..82249 /note="tyrosine kinase Hck exon 4"
exon	83420..83601 /note="tyrosine kinase Hck exon 5"
exon	142091..142310 /note="tyrosine kinase Hck exon 6"
exon	143133..143204 /note="tyrosine kinase Hck exon 7"
exon	151084..151138 /note="tyrosine kinase Hck exon 8"
exon	151354..151508 /note="tyrosine kinase Hck exon 9"
exon	153033..153166 /note="tyrosine kinase Hck exon 10"
exon	153955..154163 /note="tyrosine kinase Hck exon 11"

CDS	114740..115158 /note="EST marker AA504989"
marker	complement (67759..68150) /note="microsatellite marker D8S1695"
marker	130656..131033 /note="microsatellite marker D8S1759"

II. Genes predicted by GENSCAN only.

FEATURES	Location/Qualifiers
promoter	107727..107766 /note="putative promoter of unknown gene #1"
exon	118691..118763 /note="putative exon 1 of unknown gene #1"
exon	120794..120993 /note="putative exon 2 of unknown gene #1"
polyA_signal	121734..121739 /note="polyA site of unknown gene #1"
promoter	complement (140238..140277) /note="putative promoter of unknown gene #2"
exon	complement (137281..137287) /note="putative exon 1 of unknown gene #2"
exon	complement (133691..133885) /note="putative exon 2 of unknown gene #2"
exon	complement (124967..125115) /note="putative exon 3 of unknown gene #2"
polyA_signal	complement (122570..122575) /note="polyA site of unknown gene #2"
exon	complement (185949..186048) /note="putative exon 1 of unknown gene #3"
exon	complement (183404..183567) /note="putative exon 2 of unknown gene #3"
exon	complement (181565..181643) /note="putative exon 3 of unknown gene #3"
exon	complement (178527..178625) /note="putative exon 4 of unknown gene #3"
exon	complement (173083..173148) /note="putative exon 5 of unknown gene #3"
exon	complement (170443..170610) /note="putative exon 6 of unknown gene #3"
exon	complement (157719..157842) /note="putative exon 7 of unknown gene #3"
exon	complement (157131..157280) /note="putative exon 8 of unknown gene #3"
exon	complement (156970..157057) /note="putative exon 9 of unknown gene #3"
exon	complement (155555..155662) /note="putative exon 10 of unknown gene #3"
polyA_signal	complement (154916..154921) /note="polyA site of unknown gene #3"

Figure 4. Predicted putative genes in clone RPCI-11 589N15.




Figure 4. Putative genes in clone RPCI-11 589N15

Genes predicted by GENSCAN and by homology to the Unigene database.

FEATURES	Location/Qualifiers
exon	complement (65516..65899) /note="exon of transcriptional coactivator pc4mRNA"
exon	158970..159156 /note="exon 1 of squalene synthase gi=435676"
exon	165015..165115 /note="exon 2 of squalene synthase gi=435676"
exon	165890..166076 /note="exon 3 of squalene synthase gi=435676"
exon	60811..60940 /note="exon 4 of squalene synthase gi=435676"
exon	28685..28471 /note="exon 5 of squalene synthase gi=435676"
exon	108165..108362 /note="exon 6 of squalene synthase gi=435676"
exon	109437..109608 /note="exon 7 of squalene synthase gi=435676"
exon	116298..117234 /note="exon 8 of squalene synthase gi=435676"
exon	complement (87938..88058) /note="exon 1 of cathepsin B gi=348706"
exon	complement (87310..87429) /note="exon 2 of cathepsin B gi=348706"
exon	complement (85921..86054) /note="exon 4 of cathepsin B gi=348706"
exon	complement (84590..85484) /note="exon 5 of cathepsin B gi=348706"
exon	complement (121493..121675) /note="exon N1 of GATA-4 gi=508483"
exon	complement (120340..120471) /note="exon N2 of GATA-4 gi=508483"
exon	complement (70582..70670) /note="exon N3 of GATA-4 gi=508483"
exon	complement (68632..68783) /note="exon N4 of GATA-4 gi=508483"
exon	complement (82806..83647) /note="exon N5 of GATA-4 gi=508483"
CDS	42481..42864 /note="EST marker R01183"
CDS	81946..82373 /note="EST marker R01769"
CDS	complement (84714..85098) /note="EST marker H16027"
CDS	108843..109120 /note="EST marker Z45810"
CDS	complement (116770..117222) /note="EST marker N29512"

Appendix II.

Reprints

1. Wang, J.C., Radford, D., Wylie C., McPherson, J., Donis-Keller, H., Goate, A.. Physical mapping and identification of tumor suppressor gene candidates involved in ductal carcinoma in situ on chromosome 8p22-p23. The 200Era of Hope Proceedings, Volume 1, p151.
2. Wang, J.C., Radford, D., Holt, M., Helms, C., Goate, A., Brandt, W, Parik, M., Phillips, N.J., DeSchryver, K., Schuh, M.E., Fair, K.L., Ritter, J.H., Marshall, P., and Donis-Keller, H. (1999). Sequence-ready contig for the 1.4 cM ductal carcinoma *in situ* loss of heterozygosity region on Chromosome 8p22-23. Genomics, 60:1-11.
3. Wang, J.C., Radford, D., Holt, M., Helms, C., Brandt, W., and Donis-Keller, H. (1997). Chromosome 8p deletions in ductal carcinoma *in situ* (DCIS) of the breast. Am J Hum Genet S61:A87.
4. Radford, D.M., Fair, K.L., Phillips, N. J., Ritter, J.H., Steinbrueck, T., Holt, M.S. and Donis-Keller, H. (1995). Allelotyping of ductal carcinoma *in situ* (DCIS) of the breast; deletion of loci on 8p,13q,16q,17p and 17q. Cancer Res. 55:3399-3405.
5. Radford, D.M., Holt, M.S., Phillips, N.J., Fair, K.L., Ritter, J.H., and Donis-Keller H. (1995). Allelic loss on chromosome 8p occurs early in the development of breast carcinoma. Surgical Forum, XLVI: 533-5.
6. Radford, D.M., Phillips, N.J., Fair, K.L., Ritter, J.H., Holt, M., and Donis-Keller, H. (1995). Allelic loss and the progression of breast cancer. Cancer Res. 55:5180- 5183
7. Radford, D.M., Fair, K.L., Thompson, A.M., Ritter, J.H., Holt, M., Steinbrueck, T., Wallace, M., Wells, S.A. and Donis-Keller, H.R. (1993). Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. Cancer Res. 53:2947-2950.
8. Radford, D.M., Fair, K.L., Thompson, A.M., Ritter, J.H., Holt, M., Wells, S.A.Jr., Donis-Keller, H.R. (1993). Chromosomal regions implicated in the development of breast cancer. Surgical Forum XLIV: 502-504.

Personnel involved in this research project

Alison Goate, D.Phil.

Jen C. Wang, Ph.D.

Helen Donis-Keller, Ph.D.

Diane M. Radford, M.D.

Matt Halt

Keri Fair, B.S.

**PHYSICAL MAPPING AND THE IDENTIFICATION OF TUMOR
SUPPRESSOR GENE CANDIDATES INVOLVED IN DUCTAL
CARCINOMA *IN SITU* ON CHROMOSOME 8P22-P23.**

Jen Chyong Wang^{*}, Diane Radford^{}, Christine Wylie[†], John
McPherson[‡], Helen Donis-Keller^{*,†,‡} and Alison Goate^{*,†}**

^{*}Department of Psychiatry, [†]Department of Genetics, [‡]Division of Human Molecular
Genetics, Department of Surgery, and [§]Genome Sequencing Center, Washington
University School of Medicine, St. Louis, MO 63110; ^{**}Parkcrest Surgical Associates
Inc., St. Louis, MO 63141.

E-mail: jwang@hg.wustl.edu

From our allelotyping study of ductal carcinoma *in situ* (DCIS), we identified the smallest common region of loss of heterozygosity (LOH) to be located at chromosome 8p22-23 in an approximately 1.4-cM interval between D8S265 and D8S520. An integrated YAC/BAC clone contig covering this DCIS deletion region was constructed using the CITB BAC library. This contig spanning ~1730 kb consists of 13 YACs and 27 BACs. Eleven ESTs localized to the region near D8S550 from the UniGene map were verified by PCR assay and mapped to our contig. Eight of these 11 ESTs appeared to be unique since they did not identify homologous sequences in the publicly available databases. Two ESTs, N29512 and AA018590 identified by the marker SGC30677 in UniGene, were developed from a cDNA clone with sequence homology to human Farnesyl Diphosphate Farnesyltransferase. EST H16027 which is one of the ESTs detected by the marker WI-8953 is derived from a cDNA clone with homology to human Cathepsin B precursor. To effectively sequence the deletion region with the high through-put technique at the Genome Sequencing Center of Washington University, a second BAC library (RPCI-11) was screened using the insert end sequences of BAC clones on the YAC/BAC contig. Fifty seven RPCI BACs were isolated and incorporated into a refined sequence-ready contig by hybridization and fingerprinting. Twenty four of these clones were contained entirely within other clones. Clones forming a minimal tiling path have been subcloned into M13 and shotgun sequencing is in progress.

The U.S. Army Medical Research and Material Command under DAMD-94-J-4293 supported this work.

Sequence-Ready Contig for the 1.4-cM Ductal Carcinoma *in Situ* Loss of Heterozygosity Region on Chromosome 8p22–p23

J. C. Wang,^{*,1} D. M. Radford,^{*,2} M. S. Holt,^{*,3} C. Helms,^{*,3} A. Goate,^{†,‡,4} W. Brandt,^{*,5}
M. Parik,^{*} N. J. Phillips,[§] K. DeSchryver,[¶] M. E. Schuh,^{||} K. L. Fair,^{*} J. H. Ritter,^{**}
P. Marshall,^{*} and H. Donis-Keller,^{*,†,‡}

^{*}Department of Surgery, Division of Human Molecular Genetics, [†]Department of Genetics, [‡]Department of Psychiatry, and

^{**}Department of Pathology, Washington University School of Medicine, St. Louis, Missouri 63110; [§]Department of Pathology, St. Louis University School of Medicine, St. Louis, Missouri 63110; [¶]West Central Pathologists Inc., St. Louis, Missouri 63141; and ^{||}Parkcrest Surgical Associates Inc., St. Louis, Missouri 63141

Received April 28, 1999; accepted June 15, 1999

We report the construction of an ~1.7-Mb sequence-ready YAC/BAC clone contig of 8p22–p23. This chromosomal region has been associated with frequent loss of heterozygosity (LOH) in breast, ovarian, prostate, head and neck, and liver cancer. We first constructed a meiotic linkage map for 8p to resolve previously reported conflicting map orders from the literature. The target region containing a putative tumor suppressor gene was defined by allelotyping 65 cases of sporadic ductal carcinoma *in situ* with 18 polymorphic markers from 8p. The minimal region of loss encompassed the interval between D8S520 and D8S261, and one tumor had loss of D8S550 only. We chose to begin physical mapping of this minimal LOH region by concentrating on the distal end, which includes D8S550. A fine-structure radiation hybrid map for the region that extends from D8S520 (distal) to D8S1759 (proximal) was prepared, followed by construction of a single, integrated YAC/BAC contig for the interval. The ~1730-kb contig consists of 13 YACs and 27 BACs. Fifty-four sequence-tagged sites (STSs) developed from BAC insert end-sequences and 11 expressed sequence tags were localized within the contig by STS content mapping. In addition, four unique cDNA clones from the region were isolated and fully se-

quenced. This integrated YAC/BAC resource provides the starting point for transcription mapping, genomic sequencing, and positional cloning of this region. © 1999 Academic Press

INTRODUCTION

Chromosome loss reveals constitutional recessive mutations that can result in tumor development (Sager, 1989; Marshall, 1991). Individuals heterozygous for a mutated tumor suppressor allele express the mutant phenotype (cancer) when the normal allele is lost. Thus, loss of heterozygosity (LOH) analysis may be used to map putative tumor suppressor genes when the DNA from normal and tumor-derived cells for the same patient are compared, using polymorphic markers flanking the locus. Frequent LOH of chromosome 8p has been reported in several types of human cancer, e.g., tumors of the prostate (Vocke *et al.*, 1996), lung (Emi *et al.*, 1992; Wood *et al.*, 1994), colon (Emi *et al.*, 1992; Wood *et al.*, 1994), larynx (Sunwoo *et al.*, 1996), liver (Emi *et al.*, 1992), and breast (Chuaqui *et al.*, 1995; Kerangueven *et al.*, 1995; Adelaide *et al.*, 1998; Dahiya *et al.*, 1998).

Studies in colorectal cancer have indicated the presence of at least two tumor suppressor genes (TSG) on 8p, at 8p11–p21.3 and 8p21–p22 (Farrington *et al.*, 1996). Similarly, three distinct regions, at 8p23, 8p22, and 8p12–p21, were defined by LOH studies for prostate cancer (Bova *et al.*, 1996; Vocke *et al.*, 1996; Perinchery *et al.*, 1999) and tumors of the head and neck (Sunwoo *et al.*, 1996; Wu *et al.*, 1997). Wright *et al.* (1998) identified three regions of loss on 8p (one in 8p22 and two in 8p23) for ovarian adenocarcinomas.

Markers in the region at 8p12–p22 have been shown by linkage analysis to have significant lod scores in several German breast cancer families, suggesting that BRCA3 may reside within that region (Seitz *et al.*,

Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under Accession Nos. AF122926–AF122948, AF124266–AF124297, and AF124365–AF124368.

¹ Present address: Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110.

² Present address: Parkcrest Surgical Associates Inc., St. Louis, MO 63141.

³ Present address: Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110.

⁴ To whom correspondence should be addressed at Department of Psychiatry, Box 8134, Washington University School of Medicine, St. Louis, MO 63110. Telephone: (314) 362-8691. Fax: (314) 747-2983. E-mail: goatea@psychiatry.wustl.edu.

⁵ Present address: Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, MO 63110.

1997a,b). Recently Yokota *et al.* (1999) reported allelic loss in two regions (8p12–p21 and 8p22–p23.1, encompassing D8S549 and D8S1992) in advanced tumors, indicating that allelic loss on 8p may contribute to the progression of breast carcinoma.

In 1932 Broders proposed the term "*in situ*" to describe a condition in which malignant cells are present but have not yet penetrated the basement membrane. Ductal carcinoma *in situ* (DCIS) of the breast is a preinvasive form of breast cancer and can be a precursor of invasive ductal breast cancer. Several studies have described allelic losses in DCIS at multiple regions of chromosome 8p (Radford *et al.*, 1995; Yaremko *et al.*, 1995, 1996; Anbazhagan *et al.*, 1998), suggesting that these regions may be involved in early development of breast cancer.

The objective of our study was to map physically a genomic region defined by LOH assays of 65 DCIS tumor/normal pairs. We report DCIS allelic losses in 8p22–p23 and the construction of a 1.7-Mb sequence-ready contig from 8p22–p23 that may contain a tumor suppressor gene. Fifteen expressed sequence tags (ESTs) and cDNA clones from the region were also mapped to the contig, and nearly 25 kb of sequence was generated during the course of the study. This integrated YAC/BAC contig map provides a very useful resource for additional transcriptional mapping, positional cloning, and sequencing of this important region.

MATERIALS AND METHODS

LOH analysis. Sixty-five archival paraffin-embedded samples of DCIS were collected from several hospitals in St. Louis (Barnes-Jewish, Deaconess Central, St. Louis University, and the Outpatient Surgery Center). Subtypes of DCIS and nuclear grade were classified by the pathologists (N.J.P., J.H.R., K.DeS.). Either matched archival normal lymph node DNA or leukocyte DNA was used as a control. When it was necessary to draw blood for a normal control, informed consent was obtained following Institutional Review Board approval. Samples were microdissected to enrich for tumor cells, and DNA was purified as previously described (Radford *et al.*, 1993). After microdissection, tissue samples containing an insufficient number of tumor cells for the normal DNA extraction procedure were digested in small volumes (10–20 μ l) of lysis buffer containing proteinase K and then phenol- and chloroform-extracted once before sodium acetate/ethanol precipitation. This material was resuspended in water, and then aliquots were used directly as a template (5–10 ng) for PCR amplification. Initial PCR conditions were obtained via the Genome Data Base (GDB, <http://gdbwww.gdb.org>) and then optimized in the laboratory. PCR products were separated on 7 M urea denaturing polyacrylamide sequencing gels and dried before exposure to Kodak XAR film. LOH was determined by a combination of visual inspection and scanning densitometry of the autoradiographs (Radford *et al.*, 1995). A 2.5-fold difference in the relative allele intensity ratios between tumor and normal DNA in an informative tumor/normal pair was scored as LOH (allele1/allele2 in tumor compared to allele1/allele2 in normal). To maintain a conservative scoring approach, marginal allele reduction by inspection was not scored as LOH. Tumor samples with equivocal results were redissected in an attempt to obtain a "purer" specimen, and the experiments were repeated. All LOH designations were scored by two independent scientists and repeated to verify the result.

Genetic linkage maps. Publicly available data (<http://www.cephb.fr/cephdb/>) of 8 Centre d'Etude Polymorphisme Humaine (CEPH)

reference families from CEPH version 7 were used for loci D8S264, D8S258, and D8S133. An additional 8 CEPH families (66, 1333, 1334, 1340, 1341, 1345, 1375, and 1377) were typed for markers D8S262, D8S277, D8S439, D8S351, D8S503, D8S516, D8S552, D8S261, LPL, SFTP2, NEFL, D8S137, D8S259, PLAT, and D8S166 and then merged with other family genotypes from CEPH. For loci D8S520, D8S550, D8S265, D8S511, and D8S549, an additional 12 families were genotyped (the extra 4 families being 104, 1344, 1346, and 1408). Merged data were then processed using the linkage program CRIMAP (P. Green, unpublished data) with minimum odds for order of 1000:1 during the "build." The program permutation option "flips" was used to determine the most likely marker order from the "build" results.

Radiation hybrid (RH) maps. We used the G3 radiation hybrid mapping panel (Research Genetics, Inc., Huntsville, AL) to construct the RH placement map. This 8 Krad panel, comprising 83 RH clones representing the whole human genome, was created by the Stanford Human Genome Center and has 500-kb resolution (Stewart *et al.*, 1997). Sequence-tagged site (STS) markers were assayed by PCR amplification and sized on 3% agarose gels stained with ethidium bromide. Each assay was performed twice; i.e., PCR products at the expected size were observed on each of the duplicate gels to be scored as positive. Marker data generated using the G3 panel were submitted to the Stanford RH server (<http://www.shgc.stanford.edu/RH/rhserverformnew.html>), which subsequently returned the results of analysis with a list of the highest-linked mapped markers, the lod score of the linkage, and the distance in centirays between the submitted marker and the linked marker on the map. However, the server compares only one submitted marker and the highest-linked marker at a time. To construct a RH placement map containing all of our markers, we also used the program RHMAP, version 3.0 (Lunetta *et al.*, 1996; <http://www.sph.umich.edu/group/statgen/software>) to analyze our G3 panel data together with the RH data from two flanking markers, SHGC-1955 (AFM287we5) and SHGC-13122 (D8S2061), from Stanford's RH map (<http://www.shgc.stanford.edu/mapping/rh/>).

YAC and BAC clone contig construction. The CEPH YAC contig WC-1195 from WICGR was used for the initial contig construction. A copy of the CEPH YAC library was maintained in our laboratory, and clones used in the mapping were propagated on YPD medium plates. Ten isolated colonies from each YAC clone were tested using a "whole-cell PCR" assay to identify colonies positive for a marker(s) from the region. For whole-cell PCR, a small amount of an isolated colony was suspended in 5 μ l of deionized water, and the suspension was used directly as the template in a standard PCR. A standard ligation-mediated PCR method (Mueller and Wold, 1989; Vocero-Akbani *et al.*, 1996) was used in the development of the STS sJCW from YAC 770E9. PCR primers developed for the marker sJCW are 5'-TCAACAGCAGATTAGACACAGC-3' and 5'-GYGGCTCTTATGC-CATGTAC-3'.

For BAC contig construction, we screened the human BAC library CITB-978SK-B and CITB-HSP-C, constructed by the California Institute of Technology (obtained from Research Genetics, Inc.). The library screen involved a total of 120 PCR for each STS assay. As with YAC clone isolation, each identified BAC clone was then verified by a whole-cell PCR assay using 10 randomly selected colonies as candidates. After the positive BAC clones were verified, single BAC colonies were propagated in liquid medium, cells were harvested, and insert DNA was prepared using the Plasmid Midi-Kit from Qiagen Inc. (Chatsworth, CA). Each BAC clone was partially sequenced on an ABI 373 DNA sequencer (PE/ABI), from the insert ends using modified T7 (5'-GTAATACGACTCACTATAGGG-3') and Sp6 (5'-CGCCAAGCTATTTAGGTGACAC-3') primers. The sequence generated was analyzed for candidate PCR primer sequences using the program PRIMER 0.5 (Lincoln and Lander, MIT Center for Genome Research). STSs developed from BACs were tested using the NIGMS (No. 2) rodent/human hybrid panel, in which each hybrid cell contains a single human chromosome, and only chromosome 8-specific STSs were used as entry points for chromosome walking.




FIG. 1. LOH analysis using 18 mapped markers on 8p and one on 8q. An 80.8-cM sex-average multipoint linkage map is presented as a vertical bar to the right of the cytogenetic ideogram. Map distances are given to the left of the vertical map in cM. Genetic loci uniquely placed with odds for order of at least 1000:1 are given to the right of the map.

To estimate insert sizes, BAC clones were digested with *NotI*, and restriction fragments were separated on 1% agarose gels in 0.5× TBE buffer using MidRange II PFG markers (NE BioLabs) as size standards. Gels were electrophoresed at 6 V/cm with an initial pulse of 5 s and a final pulse of 15 s for 18 h at 14°C in a Bio-Rad CHEF DR II apparatus.

RESULTS

LOH Observed for DCIS on 8p

Sixty-five cases of DCIS were assayed for LOH using 18 mapped microsatellite markers on 8p and 1 on 8q. Of 61 samples informative for at least 1 marker on 8p, LOH was found in 17 tumor DNA samples (27.8%). Of the informative tumors, LOH was observed in 11/35 comedo, 3/14 cribriform, 1/4 solid, and 2/3 micropapillary samples. None of the 3 informative mixed and 2 informative papillary samples showed LOH. Sixteen of 44 informative samples with high nuclear grade showed LOH, 1/13 showed low nuclear grade, and 0/4 showed intermediate nuclear grade.

Ten tumor samples demonstrate loss of most of the short arm of chromosome 8 (Fig. 1). For example, tumor 6 had apparently lost an allele from all loci tested telomeric to D8S259. Tumors 56, 58, 71, and 77 contain deletions that localize the putative tumor suppressor gene between D8S520 and D8S261. Tumor 47 showed LOH for D8S550 but retained loci D8S265 and

D8S520, confining the deleted region to a minimum interval of 1.4 cM at 8p22-p23, between the markers D8S520 and D8S265 (Figs. 1 and 2). Tumor 79 showed LOH for LPL at 8p22 but retained three loci that were more telomeric, suggesting a second, more centromeric deletion region at 8p22-p23. The frequency of LOH for each marker tested is listed in Table 1. The highest rates of loss were found with markers D8S550, D8S552, and D8S503. No statistical correlation was found between LOH on 8p and histologic parameters such as subtype, nuclear grade, or the presence or absence of associated invasion. Tumor 47 showed LOH for D8S550 only, suggesting that the tumor suppressor gene would be found near this locus. Thus we concentrated our physical mapping efforts on this region.

RH Mapping of the Region near D8S550

We constructed a refined radiation hybrid map (Table 2) for the deletion interval using the Stanford G3 panel. A total of 10 markers including 6 microsatellite markers (D8S265, D8S520, D8S550, D8S1695, D8S1755, and D8S1759), one novel STS (sJCW), and 3 ESTs (A005E28, T96924, and WI-6800) that were identified through database searches were ordered on the map using our typing data and the program RHMAP, version 3.0. The marker D8S520 was mapped distal to the centromere and D8S1759 proximal to the centromere.




FIG. 2. Examples of LOH in DCIS samples. T indicates tumor DNA and N matched normal control. (a) Tumor 41 marker D8S550. The fold difference in integrated allele ratios between tumor and normal is 6.13. (b) Tumor 41 marker D8S261. The fold difference in integrated allele ratios between tumor and normal is 10.9. The upper allele is lost in the tumor in both cases. (c) Tumor 47 marker D8S550. (d) Tumor 47 marker D8S265. The lower allele is lost in the tumor for marker D8S550, but both alleles are retained for marker D8S265.

mere. The order of markers D8S265, D8S520, and D8S550 confirmed our genetic linkage map order. The order of other markers on the RH map also matched the position of those markers on our contig map except that of D8S1755 (Fig. 3, Table 2). When only 6 microsatellite markers were typed, D8S1755 was placed between markers D8S265 and D8S550, which corresponded to the contig map. However, when the RH data from 3 EST markers were integrated, D8S1755 mapped between D8S265 and D8S1759. Data errors such as false-positives or false-negatives or the limited resolution of the RH panel could explain this discrepancy. The distance of 42.3 cR, or approximately 1565 kb (assuming 37 kb per centiray; Stewart *et al.*, 1997), between the markers D8S265 and D8S520 demonstrated ~1:1 correspondence between genetic and physical distances for this interval.

Construction of an Integrated YAC/BAC Contig from D8S520 to D8S1759

We constructed a single, continuous, integrated YAC/BAC clone contig spanning a total distance of

TABLE 1
Eighteen Loci on 8p and One Locus on 8q Assayed for LOH

Locus	No. LOH ^a	No. inf. ^b	% LOH
D8S264	5	26	19.2
D8S262	7	32	21.9
D8S439	5	22	22.7
D8S351	3	18	16.6
D8S503	8	21	38
D8S516	6	26	23
D8S520	7	25	28
D8S550	8	22	36.4
D8S265	10	44	22.7
D8S552	13	32	40.6
D8S511	4	19	21
D8S549	6	19	31.6
D8S261	9	31	29
LPL	5	23	21.7
SFTP2	5	30	16.6
NEFL	5	22	22.7
D8S137	4	22	18.2
D8S259	5	26	19.2
D8S166	2	21	9.5

^a No. LOH, number of LOH cases detected from informative tumor samples tested for the marker.

^b No. inf., number of informative samples observed from 65 tumor cases tested.

~1730 kb covering the putative TSG region of ~1100 kb based on sizes of BAC clones. This sequence-ready contig comprises 13 YACs and 27 BACs including 54 STSs from BAC end sequences (Table 3).

YAC Clone Contig

Based on the publicly available contig maps from WICGR (<http://carbon.wi.mit.edu>), we isolated 13 YACs using the six microsatellite markers listed in RH

TABLE 2
RH Map Spanning the Deletion Interval

Marker	Distance (cR)
Telomere	
SHGC-1955	
(AFM287we5)	4.7
A005E28	4.8
sJCW	4.9
D8S520	20.8
D8S550	16.2
W1-6800	0.0
T96924	5.3
D8S265	20.6
D8S1755	17.6
D8S1759	0.0
D8S1695	11.6
SHGC-13122	
(D8S2061)	
Centromere	

Note. 1 cR \approx 37 kb (Stewart *et al.*, 1997). Boldface type indicates markers we assayed using the Stanford G3 panel.



TABLE 3

Primer Sequences and Annealing Temperatures for 54 Novel STS Markers on BAC Contig

STS	PCR primer	GenBank Accession No.	Product size (bp)	Annealing temperature (°C)
17H6-Sp ₆	5'-CAGCCCTCAACAAAGGTAGG-3'/5'- CTCTTTCAGGTGTGGCCATT-3'	AF122927	117	56
17H6-T ₇	5'-TCTTCACCTCGTGGCACTG-3'/5'- GGACAATCCATCCATCCATC-3'	AF122928	198	55
37M9-Sp ₆	5'-GGCTTGTTTGTGGGCTTATA-3'/5'- GGTGAGTTTCAAGAGGGGTT-3'	AF122943	148	56
37M9-T ₇	5'-TAACACTCTCCTGCACTCTGCCTC-3'/5'- AATGTCGTCTTCCCTGCCCAAAGG-3'	AF122944	198	62
41G3-Sp ₆	5'-ACAAGCTAAGGGCCATCCTT-3'/5'- GATGCCACCAGCATGTGG-3'	AF122933	126	56
41G3-T ₇	5'-GGTATTTGTGAGCCTTCCCA-3'/5'- GAAACACAGCACACGATAGCA-3'	AF122934	228	59
65L19-Sp ₆	5'-CCCAAAACAGTCATTGAAACG-3'/5'- CGATAAATGCTTGCTTCATCC-3'	AF122931	143	54
65L19-T ₇	5'-GGGAAACAGGCACTTCACAT-3'/5'- TTTGATCATGGGGTGGATTT-3'	AF122932	163	56
163M3-Sp ₆	5'-ACTCAACCTCCTGGGTTCCT-3'/5'- GTTGACAGCCTCACCTGTT-3'	AF122937	133	58
163M3-T ₇	5'-CTCCTCACTTGGGAAATGTG-3'/5'- CTCCAAGAAAATGATGACTGC-3'	AF122938	127	58
209H14-Sp ₆	5'-CCAGCTTCCCTTTGAGACAG-3'/5'- AGGCAGGGCTTACTTCACCT-3'	AF124288	136	58
209H14-T ₇	5'-GACTCAGTTGCTTCCAAGGC-3'/5'- TCAGCCATCAAGCTTCACAG-3'	AF124289	108	58
230B4-Sp ₆	5'-TGATCCAGGGACAGAGCAAGAAG-3'/5'- GAGCCAGGAGCATGAGAATATGG-3'	AF122939	121	62
230B4-T ₇	5'-CCATCTTTATTCCACAGGAAGAGG-3'/5'- GCAACAAGAGTGAAACTCCGTCTC-3'	AF122940	180	62
258A2-Sp ₆	5'-CCAACCTAGCCGTGGTTAGT-3'/5'- TGTGTTCAATCACCATTGGGT-3'	AF124276	162	57
258A2-T ₇	5'-CATCAGGCATTGAAGTCACA-3'/5'- TAAGCACGCACACAGCC-3'	AF124277	146	55
263K8-Sp ₆	5'-TGAGCACACAGGATTTTACG-3'/5'- CGTCATCATACCCAGAGTC-3'	AF124266	150	55
263K8-T ₇	5'-TCTCGTTTGCTTATGACCTG-3'/5'- CTAACAACCTAGATTGGAAGGAGC-3'	AF124267	138	57
269E3-Sp ₆	5'-AGTGCTGGGGGGGATTTTGTG-3'/5'- ACGTGGCAGTGGGTTAGAGTTG-3'	AF124290	148	61
269E3-T ₇	5'-GCAGCTGATCTCTCTCCACC-3'/5'- CCTTTCCTCCATGTTGGCT-3'	AF124291	202	58
271O23-Sp ₆	5'-GTCTTGGGGGTCAAAAATCT-3'/5'- GCTTGTGTATCCACTCCGTT-3'	AF124284	131	56
271O23-T ₇	5'-TGCCCACTTTCCCTCATGG-3'/5'- TTCTAAGCCAGTGAGTTGATGC-3'	AF124285	155	57
321I17-Sp ₆	5'-TGTGCGCATAGTAGGAATGA-3'/5'- CGCAAAAAGGTGAGAGAGAG-3'	AF122941	213	57
321I17-T ₇	5'-ACTCAACCTCCTGGGTTCCT-3'/5'- TCTGAGCTCCTTTCCACGT-3'	AF122942	151	57
327I14-Sp ₆	5'-TGAAGGTCTGCTCAGCACC-3'/5'- CCTGCAAAAAGGCTGACCTAG-3'	AF124292	199	59
327I14-T ₇	5'-CATCTGTTGATGGGCATTTG-3'/5'- TGGCAATCCCCCTTCTAAG-3'	AF124293	138	55
337E21-Sp ₆	5'-ATATGTGCACCCAATGCAG-3'/5'- GAGTTCAATTACGGGATAGCC-3'	AF124272	174	56
337E21-T ₇	5'-TAACCGTGACACTCTACTGCC-3'/5'- TTCATGATCTCAAGGCTGTG-3'	AF124273	203	53

TABLE 3—Continued

STS	PCR primer	GenBank Accession No.	Product size (bp)	Annealing temperature (°C)
358B10-Sp ₆	5'-TGCTGTGCTAGCCAGTTCC-3'/5'- AACAGGTACCACAAGGCAGC-3'	AF124294	178	60
358B10-T ₇	5'-GCCCTTGCTTAAGAACTCAA-3'/5'- ACCCAGGCATATTGGTGAGT-3'	AF124295	205	56
362D2-Sp ₆	5'-TGCAGCCTCATTCTGTTGTC-3'/5'- CTCATCAGKGAGTCTGGAGTCG-3'	AF124274	133	57
362D2-T ₇	5'-ATAGGGTTGACACTGCCACC-3'/5'- TTGGCCAGGCATGGTAGT-3'	AF124275	132	58
367I24-Sp ₆	5'-AAGGAAGCGCCCAATTC-3'/5'- ACTGGCTTTGCTGGAATTTT-3'	AF124286	120	56
367I24-T ₇	5'-TGCTGAGCTGGGTGAAATC-3'/5'- CCATGAAGGAAAGGACCTGA-3'	AF124287	147	56
426H2-Sp ₆	5'-CCCCAAACGTATCAATCCAG-3'/5'- TCCATTTCCAGTGTGTTGGA-3'	AF122945	167	59
426H2-T ₇	5'-TGACAGAAGGATCTGGGACC-3'/5'- GGAAGTTGAGGCTGCAGAGA-3'	AF122946	181	60
432L12-Sp ₆	5'-AAAGGGGAGACATTCGGC-3'/5'- TGGGAGGAGAGAGCCAGATA-3'	AF124268	149	56
432L12-T ₇	5'-AACCTGCACTGCCAATAACC-3'/5'- AAGGTTTTGTGACCTCGGG-3'	AF124269	147	54
435N19-Sp ₆	5'-CTTTTGGTCAAAGCCCACAT-3'/5'- TTGCAGTGAAGGCTGAAATG-3'	AF124296	118	54
435N19-T ₇	5'-TGTGTTAGATGATTTTGCCCA-3'/5'- ATATGCCTAGCCTACCAAACA-3'	AF124297	100	57
468L5-Sp ₆	5'-ACCCAACAACGCCATAAAAC-3'/5'- GTGGGGGTGTTTTTCTTGTC-3'	AF122935	162	58
468L5-T ₇	5'-TTCCTTCCACTGGATACGC-3'/5'- TTTTCTGTGGTGGGGTAGAC-3'	AF122936	141	57
479G14-Sp ₆	5'-GCACAGAGGATTTTTACGGC-3'/5'- ACACGTCATCATCACCAGA-3'	AF124270	150	60
479G14-T ₇	5'-CACCAGAGAGGTGCAAAAACA-3'/5'- TTGCAGCCAAGTGGTATTG-3'	AF124271	156	56
493P15-Sp ₆	5'-ACCATCAAGCAACTWGGTTTCCAG-3'/5'- TTCATGMTGACTTGGGGTGC-3'	AF124278	145	58
493P15-T ₇	5'-CCATGCTACCATTGCACTCCTC-3'/5'- TTGATGGGATGTGGGGCAAAGTGG-3'	AF124279	143	61
516O23-Sp ₆	5'-TCTGCCACGTTTTTGGTATCAGG-3'/5'- AAATCCCTGGACACACACACCC-3'	AF124280	257	63
516O23-T ₇	5'-TCTTCAAGACCCATGCCTG-3'/5'- GGCATACATCACCATGCTCA-3'	AF124281	278	56
516P13-Sp ₆	5'-TGGCTTAGTGCTAACCCTCA-3'/5'- ATGTTGGAGTCCTAAAACCTCG-3'	AF122929	101	54
516P13-T ₇	5'-CATAGAGGCATTTTGGTTACG-3'/5'- ATGGAAAAGAGATCTAACAGCG-3'	AF122930	102	54
525F1-Sp ₆	5'-CCTGGGTTCTCTCGTGAATCTTC-3'/5'- TCCTTTTCCACGTTGACAGCC-3'	AF122947	136	62
525F1-T ₇	5'-GGTACTATCCACACTCGTTGGGGT-3'/5'- AACATGCAATACCAAGGATGCG-3'	AF122948	122	60
573G21-Sp ₆	5'-CTGCCTCCTGCAAAATTTGT-3'/5'- CGAGCACCAGATTTGCTTTT-3'	AF124282	196	57
573G21-T ₇	5'-ACCCATCATCCCTGGAAG-3'/5'- GTAGTGCCAATTCCCTTTCA-3'	AF124283	127	56

mapping and one additional marker, WI-8953, that appeared to fall within the relevant interval. We confirmed the presence of these markers within the YAC

clones 700D3, 710A5, 715C10, 723F10, 729E12, 737E5, 749H6, 770E9, 807F11, 809H8, 894G12, and 915H4 (Fig. 3).

BAC Library Screening

The initial screening of the human BAC library was conducted with 10 markers including 6 microsatellite markers (D8S520, D8S550, D8S1755, D8S265, D8S1695, and D8S1759) and 4 ESTs (T96924, WI-6800, N29512, and Z45810) anchored on the YAC contig (Fig. 3). An average of 5 BAC clones per marker were identified and isolated using PCR assays. After the positive BAC clones were verified, the insert ends of each clone were sequenced. The chromosomal origin of each newly generated STS was verified using a panel of rodent/human hybrids. Only the clones containing chromosome 8-specific STSs at both ends were used for contig construction.

Chromosome Walking

From our initial screening, we were able to build a continuous BAC clone contig from D8S550 to D8S1759, leaving a gap between the markers D8S520 and D8S550 (Fig. 3). To close the gap, STSs developed from T7-end sequences of clones 263K8 and 337E21 were used for secondary BAC library screening. Three clones, 163M3, 321I17, and 525F1, and one clone, 426H2, were identified and isolated from STSs 263K8-T7 and 337E21-T7, respectively. Both insert ends of these newly isolated BAC clones were sequenced, and six chromosome 8-specific STSs were generated. Six STSs (163M3-Sp6, 163M3-T7, 321I17-Sp6, 321I17-T7, 525F1-Sp6, and 426H2-T7) were mapped back onto the YAC/BAC contig using PCR assays, leaving a gap between 525F1-T7 and 426H2-Sp6. From another BAC library screening experiment, five clones were identified and isolated using a PCR assay from the STS 426H2-Sp6; four of them were found to be positive for the STS from 525F1-T7. Among these, four novel STSs (37M9-Sp6, 37M9-T7, 230B4-Sp6, and 230B4-T7) were developed from insert end sequences and mapped back to the contig by overlap analysis (Fig. 3). This completed construction of a continuous BAC clone-based contig of the region.

All of the 27 BAC clones used for contig construction were digested with restriction enzyme *Not*I, from which estimates of the sizes of the clones could be made. This information enabled more precise determination of the size of the region spanned by the contig and of the region containing the putative TSG. Based on the estimated sizes of the BAC clones, the contig spans approximately 1730 kb and the LOH deletion region between D8S520 and D8S265 spans ~1100 kb (Table 4).

TSG Candidate Identification and Database

Homologies

First, databases were searched for candidate genes within the region of chromosome 8p22–p23. We verified by PCR assay the locations of 11 ESTs reported to map within this region. EST A005E28 identified by the

TABLE 4

BAC Clones Mapped on the Contig Spanning the 1.1-cM Deletion Interval

Clone	Size (kb)
17H6	175 ^a
37M9	90 ^a
41G3	— ^b
65L19	258
163M3	93
209H14	—
230B4	143
258A2	130
263K8	178
269E3	172 ^a
271O23	135 ^a
321I17	100
327I14	—
337E21	255
358B10	140 ^a
362D2	135 ^a
367I24	121
426H2	170 ^a
431L12	114 ^a
435N19	—
468L5	—
479G14	125 ^a
493P15	170 ^a
516O23	175 ^a
516P13	121
525F1	127 ^a
573G21	—

Note. —, clones not sized.

^a Clones used to construct the minimal clone set for the contig spanning the region between markers of D8S520 and D8S1759.

Institute for Genomic Research (TIGR) mapped to YAC 770E9. Like STS sJCW, it tested positive for BAC clones 17H6, 65L19, and 516P13. EST T90820 also tested positive for BAC clones 65L19 and 516P13, but not for YAC 770E9 (Table 5). EST T96924 mapped to YACs 770E9, 915H4, 715C10, 737E5, and 729E12. It also tested positive for BAC clones 271O23 and 367I24 identified by D8S265. Two cDNA clones (T96924, 0.8 kb, and W67504, 1.6 kb) were isolated and fully sequenced. The two sequences were compiled into one continuous sequence using ClustalW alignment of MacVector 6.0 program (Oxford Molecular, <http://www.oxmol.com/>). This sequence contains (CA)₂₂ repeats that could be used to develop a microsatellite marker. BAC clones 271O23 and 367I24 were also partially sequenced with a primer selected from the 3' end of cDNA T96924. The sequences from these two BAC clones contain a (CA)₂₂ repeat and match the sequence from cDNA W67504.

A cluster of 6 ESTs that appeared to localize to the region from the UniGene (<http://www.ncbi.nlm.nih.gov/UniGene>) map were placed at the proximal end of our YAC/BAC contig. They all mapped to YAC 809H8. EST R01769 tested positive for BAC clones 358B10 and 435N19. ESTs AA018590, N29512, R01183, and Z45810 tested positive for clone 358B10 only. EST H16027 did not identify any BAC clone on the contig

TABLE 5
Eleven ESTs Mapped to the YAC/BAC Contig

ESTs	Accession No.	Marker name	UniGene	Mapping data
R55759	G26262	A005E28	Unidentified, Hs. 26458	BAC 17H6, 65L19, 516P13
T90820	G19346	SHGC-17264	Unidentified, Hs. 133548	BAC 65L19, 516P13
R01769	G28044	SHGC-33472	Unidentified, Hs. 119611	YAC 809H8; BAC 358B10, 435N19
R01183	R01183	stSG327	Unidentified, Hs. 4883	YAC 809H8; BAC 358B10
T96924	T96924	SGC33822	Unidentified, Hs. 35453	YAC 715C10, 729E12, 737E5, 770E9; BAC 271O23, 367I24
N29512	N29512	SGC30677	Farnesyl-diphosphate farsyltransferase, Hs. 48876	YAC 809H8; BAC 358B10
AA018590	AA018590	SGC30677	Farnesyl-diphosphate farsyltransferase, Hs. 48876	YAC 809H8; BAC 358B10
Z45810	Z45810	A005M25	Unidentified, Hs. 94151	YAC 809H8; BAC 358B10
W68256	W68256	SHGC-24302	Unidentified, Hs. 27194	YAC 710A5, 715C10, 729E12, 737E5, 770E9; BAC 516O23, 573G21
AA504989	AA504989		Unidentified	YAC 715C10, 729E12, 737E5, 770E9; BAC 271O23, 367I24, 269E3
H16027	H16027	WI-8953	Cathepsin B precursor, Hs. 84898	YAC 809H8

(Table 5). Eight of these 11 ESTs appeared to be unique since they did not identify homologous sequences in the publicly available databases. ESTs N29512 and AA018590 identified by the marker SGC30677 in UniGene were developed from cDNA clones with sequence homology to human farnesyl diphosphate farnesyltransferase. EST H16027, which is one of the ESTs detected by the marker WI-8953, is derived from a cDNA with homology to human cathepsin B precursor.

In addition to the previously reported ESTs from the region, both end sequences generated from BAC clones were analyzed with BLASTN. Only the Sp6-end sequence from clone 269E3 identified a homologous sequence, Stratagene's fetal retina *Homo sapiens* cDNA clone (AA504989). About 1.5 kb of this cDNA clone has been sequenced. Another cDNA clone (W68256, 0.6 kb) identified by the marker WI-6800 was isolated, and the insert was fully sequenced. A total of nearly 25 kb of sequence was generated from BAC insert ends and four cDNA inserts.

DISCUSSION

DCIS is a preinvasive form of breast cancer that is being detected at an increasing rate due to screening mammography. In some cases it represents a step in the pathway to invasive breast cancer, although it is not always an obligate precursor (Rogers, 1987). In our study of 65 cases of DCIS, using 18 markers on 8p and 1 on 8q, LOH was seen on 8p in 29% of informative cases. Our data identify the smallest common region of LOH to be located at 8p22-p23 in an approximately 1.4-cM region between D8S265 and D8S520. The pattern of LOH for tumor 79 suggests the presence of at least one other tumor suppressor gene proximal to the 8p22-p23 locus.

Other studies have also reported evidence of LOH on 8p in DCIS (Aldaz *et al.*, 1995; Seitz *et al.*, 1997b;

O'Connell *et al.*, 1998; Anbazhagan *et al.*, 1998). Anbazhagan *et al.* (1998) found the most common region of loss in 60 invasive ductal breast tumors to be at 8p21.3-p23.3 between D8S560 and D8S518. The 1.4-cM region of loss we have identified lies within this region. Several studies have attempted to correlate 8p LOH and the ability of a tumor to metastasize (Aldaz *et al.*, 1995; Yaremko *et al.*, 1996; Anbazhagan *et al.*, 1998; Dahiya *et al.*, 1998). Yokota *et al.* (1999) observed a minimal region of LOH on 8p, in a region flanked by markers D8S511 and D8S1991, that was associated with advanced tumor stage and aggressive histologic subtype. This region does not overlap with our minimal region. However, the two studies analyze different tumor types. In our data we observed no correlation between LOH on 8p and tumor grade or the presence of an invasive component. Both observations are thus consistent with the presence of more than one putative tumor suppressor gene on 8p, one associated with early events in breast oncogenesis and one associated with tumor invasion.

Chromosome 8p22-p23 has also been associated with potential tumor suppressor genes involved in other types of human cancers. Wright *et al.* (1998) defined three LOH regions of overlap in ovarian cancer, one at 8p22, near marker LPL, and two at 8p23, near D8S549 and the region distal to D8S1759, with the highest LOH rates at D8S264, D8S550, and D8S1827. Frequent allelic losses at D8S550 have also been observed in hepatocellular carcinoma (Nagai *et al.*, 1997). Thus it is likely that a putative tumor suppressor gene in the region of D8S550 may be involved not only in preinvasive breast cancer but also in other human cancers.

To clone and characterize efficiently the putative tumor suppressor gene in this region of 8p22-p23, we constructed a meiotic linkage map to resolve the ambiguity of marker order within this region. A radiation

hybrid map for the 1.4-cM LOH deletion interval in the region was also constructed. The recently published GeneMap'98 (Deloukas *et al.*, 1998; <http://www.ncbi.nlm.nih.gov/genemap98>) has several positional discrepancies between GB4 and G3 RH maps in the deletion interval. For example, marker WI-6800 was placed distal to D8S520 on the GB4 map while the G3 map placed WI-6800 proximal to D8S550. A direct comparison of the two RH maps reveals a limited number of shared STSs; thus precise marker orders cannot be determined from these data. When comparing markers D8S520, D8S550, WI-6800 (SHGC-24302), and SGC33822 (T96924), our RH data agreed more closely with the locus order on the G3 map than that on the GB4 map. Although our RH map position for the marker D8S1759 is different from that on the G3 map, the position was verified with our BAC clone-based contig.

Previously, physical maps that include part of 8p22-p23 have been constructed based primarily on assembly of existing YAC contigs or RH mapping (Bookstein *et al.*, 1994; Bova *et al.*, 1996; Farrington *et al.*, 1996). However, the calculated order and the distances between loci can be affected by the rearrangements, internal deletions, and chimerisms that can occur in YACs. We have confirmed marker orders with BAC clones, which are known to have low frequencies of these events. Our integrated YAC/BAC contig, extending from the distal marker 65L19-Sp6 (~200 kb distal to D8S520) to the proximal marker WI-8953 (~100 kb centromeric to D8S1759), has enabled a more precise measurement of the physical distance and marker order of the 8p22-p23 region. The contig is also a valuable framework to integrate additional cDNAs, STSs, and ESTs reported in the region. Eleven ESTs (Fig. 3, Table 5) were placed onto the clone contig, and they will be used for preliminary candidate gene analysis.

Additional genes of interest from this region may be found in the literature. Hughes *et al.* (1998) found a novel amplicon at 8p22-p23 resulting in cathepsin B (CTSB), a cancer-related gene that is overexpressed in esophageal adenocarcinoma. The EST H16027, which is similar to the CTSB gene, maps to the proximal boundary of the contig at the marker WI-8953 (Fig. 3, Table 5) and may represent this gene. Harder *et al.* (1997) isolated the gene for human β -defensin-2 (human BD-2, also known as DEFB2), and mapped it to YAC clone 773G4, within the preexisting 8p22-p23 YAC contig WC-1195, which is anchored to our contig by the marker D8S1695.

The STS information and the overlapping BAC clones presented in this report provide the starting material for large-scale sequencing of this genomic region. The contig will also be a useful resource contributing to gene identification and studies of gene expression patterns in the region.

ACKNOWLEDGMENTS

The authors are grateful to J. Wasson for his assistance in sequencing BAC insert ends, to S. Scholnick and J. Sunwoo for sharing primers for the LOH study and for helpful advice, to V. Herrmann for access to clinical information, and to R. Souvenir for technical assistance. We thank T. and M. Christ for their financial contribution and the Monsanto Co. for matching funds. This study is supported by an American Cancer Society Career Development Award and USARDC Grant DAMD-94-J-4293 (to D.M.R.) and in part by NIH Grants HG00469 and HG01066 (to H.D.K.) and a NIH Career Development Award (to A.G.).

REFERENCES

- Adelaide, J., Chaffanet, M., Imbert, A., Allione, F., Geneix, J., Popovici, C., van Alewijk, D., Trapman, J., Zeillinger, R., Borresen-Dale, A. L., Lidereau, R., Birnbaum, D., and Pebusque, M. L. (1998). Chromosome region 8p11-p21: Refined mapping and molecular alterations in breast cancer. *Genes Chromosomes Cancer* **22**: 186-199.
- Aldaz, C. M., Chen, T., Sahin, A., Cunningham, J., and Bondy, M. (1995). Comparative allelotyping of *in situ* and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinomas. *Cancer Res.* **55**: 3976-3981.
- Anbazzhagan, R., Fujii, H., and Gabrielson, E. (1998). Allelic loss of chromosomal arm 8p in breast cancer progression. *Am. J. Pathol.* **152**: 815-819.
- Bookstein, R., Levy, A., MacGrogan, D., Lewis, T. B., Weissenbach, J., O'Connell, P., and Leach, R. J. (1994). Yeast artificial chromosome and radiation hybrid map of loci in chromosome band 8p22, a common region of allelic loss in multiple human cancers. *Genomics* **24**: 317-323.
- Bova, G. S., MacGrogan, D., Levy, A., Pin, S. S., Bookstein, R., and Isaacs, W. B. (1996). Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. *Genomics* **35**: 46-54.
- Broders, A. C. (1932). Carcinoma *in situ* contrasted with benign penetrating epithelium. *J. Am. Med. Assoc.* **99**: 1670-1674.
- Chuaqui, R. F., Sanz-Ortega, J., Vocke, C., Linehan, W. M., Sanz-Espenera, J., Zhuang, Z., Emmert-Buck, M. R., and Merino, M. J. (1995). Loss of heterozygosity on the short arm of chromosome 8 in male breast carcinomas. *Cancer Res.* **55**: 4995-4998.
- Dahiya, R., Perinchery, G., Dong, G., and Lee, C. (1998). Multiple sites of loss of heterozygosity on chromosome 8 in human breast cancer has differential correlation with clinical parameters. *Int. J. Oncol.* **12**: 811-816.
- Deloukas, P., Schuler, G. D., Gyapay, G., Beasley, E. M., Soderlund, C., Rodriguez-Tome, P., Hui, L., Matise, T. C., McKusick, K. B., Beckmann, J. S., Bentolila, S., Bihoreau, M.-T., Birren, B. B., Browne, J., Butler, A., Castle, A. B., Chiannilkulchai, N., Clee, C., Day, P. J. R., Dehejia, A., Dibling, T., Drouot, N., Duprat, S., Fizames, C., Fox, S., Gelling, S., Green, L., Harrison, P., Hocking, R., Holloway, E., Hunt, S., Keil, S., Lijnzaad, P., Louis-Dit-Sully, C., Ma, J., Mendis, A., Miller, J., Morissette, J., Muselet, D., Nusbaum, H. C., Peck, A., Rozen, S., Simon, D., Slonim, D. K., Staples, R., Stein, L. D., Stewart, E. A., Suchard, M. A., Thangarajah, T., Vega-Czarny, N., Webber, C., Wu, X., Hudson, J., Auf-fray, C., Nomura, N., Sikela, J. M., Polymeropoulos, M. H., James, M. R., Lander, E. S., Hudson, T. J., Myers, R. M., Cox, D. R., Weissenbach, J., Boguski, M. S., and Bentley, D. R. (1998). A physical map of 30,000 human genes. *Science* **282**: 744-746.
- Emi, M., Fujiwara, Y., Nakajima, T., Tsuchiya, E., Tsuda, H., Hirohashi, S., Maeda, Y., Tsuruta, K., Miyaki, M., and Nakamura, Y. (1992). Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer and lung cancer. *Cancer Res.* **52**: 5368-5372.
- Farrington, S. M., Cunningham, C., Boyle, S. M., Wyllie, A. H., and Dunlop, M. G. (1996). Detailed physical and deletion mapping of

- 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer. *Oncogene* **12**: 1803-1808.
- Harder, J., Siebert, R., Zhang, Y., Matthiesen, P., Christophers, E., Schlegelberger, B., and Schroder, J.-M. (1997). Mapping of the gene encoding human β -defensin-2 (DEFB2) to chromosome region 8p22-23.1. *Genomics* **46**: 472-475.
- Hughes, S. J., Glover, T. W., Zhu, X.-X., Kuick, R., Thoraval, D., Orringer, M. B., Beer, D. G., and Hanash, S. (1998). A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. *Proc. Natl. Acad. Sci. USA* **95**: 12410-12415.
- Ishwad, C. S., Shuster, M., Bockmuhl, U., Thakker, N., Shah, P., Toomes, C., Dixon, M., Ferrell, R. E., and Gollin, S. M. (1999). Frequent allelic loss and homozygous deletion in chromosome band 8p23 in oral cancer. *Int. J. Cancer* **80**: 25-31.
- Kerangueven, F., Essioux, L., Dib, A., Noguchi, T., Allione, F., Geniec, J., Longy, M., Lidereau, R., Eisinger, F., Pebusque, M.-J., Jacquemier, J., Bonaiti-Pellie, C., Sobol, H., and Birnbaum, D. (1995). Loss of heterozygosity and linkage analysis in breast carcinoma: Indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene* **10**: 1023-1026.
- Lunetta, K., Boehnke, M., Lange, K., and Cox, D. R. (1996). Selected locus and multiple panel models for radiation hybrid mapping. *Am. J. Hum. Genet.* **59**: 717-725.
- Marshall, C. J. (1991). Tumor suppressor genes. *Cell* **64**: 313-326.
- Mueller, P. R., and Wold, B. (1989). In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. *Science* **246**: 780-786.
- Nagai, H., Pineau, P., Tiollais, P., Buendia, M. A., and Dejean, A. (1997). Comprehensive alleotyping of human hepatocellular carcinoma. *Oncogene* **14**: 2927-2933.
- O'Connell, P., Pekkel, V., Fuqua, S. A. W., Osborne, C. K., Clark, G. M., and Allred, D. C. (1998). Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. *J. Natl. Cancer Inst.* **90**: 697-703.
- Perinchery, G., Bukurov, N., Nakajima, K., Chang, J., Hooda, M., Bookstein, R., and Dahiya, R. (1999). Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate cancer. *Int. J. Oncol.* **14**: 495-500.
- Radford, D. M., Fair, K., Thompson, A. M., Ritter, J. H., Holt, M. S., Wallace, M. W., Wells, S. A., Jr., and Donis-Keller, H. R. (1993). Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res.* **53**: 2947-2950.
- Radford, D. M., Fair, K. L., Phillips, N. J., Ritter, J. H., Steinbrueck, T., Holt, M. S., and Donis-Keller, H. R. (1995). Allelotyping of ductal carcinoma *in situ* (DCIS) of the breast; deletion of loci on 8p,13q,16q,17p and 17q. *Cancer Res.* **55**: 3399-3405.
- Rogers, L. W. (1987). Carcinoma *in situ* (CIS). In "Diagnostic Histopathology of the Breast" (D. L. Page and T. J. Anderson, Eds.), Churchill Livingstone, Edinburgh.
- Sager, R. (1989). Tumor suppressor genes: The puzzle and the promise. *Science* **246**: 1406-1413.
- Seitz, S., Rohde, K., Bender, E., Nothnagel, A., Pidde, H., Ullrich, O.-M., El-Zehairy, A., Haensch, W., Jandrig, B., Kolble, K., Schlag, P. M., and Scherneck, S. (1997a). Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p12-p22 in breast carcinogenesis. *Br. J. Cancer* **76**: 983-991.
- Seitz, S., Rohde, K., Bender, E., Nothnagel, A., Kolble, K., Schlag, P. M., and Scherneck, S. (1997b). Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: Linkage analysis in German breast cancer families. *Oncogene* **14**: 741-743.
- Stewart, E. A., McKusick, K. B., Aggarwal, A., Bajorek, E., Brady, S., Chu, A., Fang, N., Hadley, D., Harris, M., Hussain, S., Lee, R., Mararukulam, A., O'Connor, K., Perkins, S., Piercy, M., Qin, F., Reif, T., Sanders, C., She, X., Sun, W. L., Tabar, P., Voyticky, S., Coeles, S., Fan, J. B., Mader, C., Quackenbush, J., Myers, R. M., and Cox, D. R. (1997). An STS-based radiation hybrid map of the human genome. *Genome Res.* **7**: 422-433.
- Sunwoo, J. B., Holt, M. S., Radford, D. M., Decker, C., and Scholnick, S. (1996). Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. *Genes Chromosomes Cancer* **16**: 164-169.
- Vocero-Akbani, A., Helms, C., Wang, J.-C., Sanjurjo, F. J., Korte-Sarfaty, J., Veile, R. A., Liu, L., Jauch, A., Burgess, A. K., Hing, A., Holt, M. S., Ramachandra, S., Whelan, A. J., Anker, R., Ahrent, L., Chen, M., Gavin, M. R., Iannantuoni, K., Morton, S. M., Pandit, S. D., Read, C. M., Steinbrueck, T., Warlick, C., Smoller, D. A., and Donis-Keller, H. (1996). Mapping human telomere regions with YAC and P1 clones: Chromosome specific markers for 27 telomeres including 149 STSs and 24 polymorphisms for 14 proterminal regions. *Genomics* **36**: 492-506.
- Vocke, C. D., Pozzatti, R. O., Bostwick, D. G., Florence, C. D., Jennings, S. B., Strup, S. E., Duray, P. H., Liotta, L. A., Emmert-Buck, M. R., and Linehan, W. M. (1996). Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. *Cancer Res.* **56**: 2411-2416.
- Wood, S., Yaremko, M. L., Schertzer, M., Keleman, P. R., Minna, J., and Westbrook, C. A. (1994). Mapping of the pulmonary surfactant SP5 (SFTP2) locus to 8p21 and characterization of a microsatellite repeat marker that shows frequent loss of heterozygosity in human carcinomas. *Genomics* **24**: 597-600.
- Wright, K., Wilson, P. J., Kerr, J., Do, K., Hurst, T., Khoo, S.-K., Ward, B., and Chenevix-Trench, G. (1998). Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. *Oncogene* **17**: 1185-1188.
- Wu, C. L., Roz, L., Sloan, P., Read, A. P., Holland, S., Porter, S., Scully, C., Speight, P. M., and Thakker, N. (1997). Deletion mapping defines three discrete areas of allelic imbalance on chromosome arm 8p in oral and oropharyngeal squamous cell carcinomas. *Genes Chromosomes Cancer* **20**: 347-353.
- Yaremko, M. L., Recant, W. M., and Westbrook, C. A. (1995). Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers. *Genes Chromosomes Cancer* **13**: 186-191.
- Yaremko, M. L., Kutza, C., Lyzak, J., Mick, R., Recant, W. M., and Westbrook, C. A. (1996). Loss of heterozygosity from the short arm of chromosome 8 is associated with invasive behavior in breast cancer. *Genes Chromosomes Cancer* **16**: 189-195.
- Yokota, T., Toshimoto, M., Akiyama, F., Sakamoto, G., Kasumi, F., Nakamura, Y., and Emi, M. (1999). Localization of a tumor suppressor gene associated with the progression of human breast carcinoma within a 1-cM interval of 8p22-p23.1. *Cancer* **85**: 447-452.

479

Chromosome 8p deletions in ductal carcinoma *in situ* (DCIS) of the breast. J. C. Wang, D. Radford, M. Holt, C. Helms, W. Brandt, and H. Donis-Keller. Div. Hum. Mol. Genet., Dept. Surgery, Washington University School of Medicine, St. Louis, MO.

In order to efficiently clone and characterize a putative tumor suppressor gene for DCIS that we have mapped within chromosome 8p (Radford et al., 1995, *Can. Res.* 55:3399), we are constructing a fine structure integrated physical and genetic map for this region. A linkage map was first constructed using 23 markers we genotyped through the CEPH reference pedigrees with loci uniquely placed (odds for order 1000:1). The map extends from the telomere of 8p to just beyond the centromere (80.8 cM). The average distance between markers is 3.5 cM.

Based on this map, 18 markers on 8p and two 8q markers were selected for LOH analysis with 65 examples of microdissected DCIS. Of 61 informative specimens, LOH was observed for at least one marker on 8p in 17 tumors (28%). Ten tumors have lost a large portion of the short arm. The smallest common region of deletion localizes to a region of 1.4 cM on 8p22-23. To refine this region, six markers were used to screen Stanford G3 and Genebridge 4 RH panels. The data from the Stanford G3 panel were analyzed and a RH map has been constructed using RHMAPPER. The map spans 17.1 cR in distance with the marker D8S520 placed distal to the centromere and D8S1759 proximal to the centromere. The data from the GB4 panel were submitted to the WICGR Mapping Service center and the order of these six markers has been determined. The locations of D8S520 and D8S1759 were confirmed, however the position of D8S265, D8S1755, and D8S1695 differ from the position found on the G3 RH map. Currently we are using 7 markers and 4 ESTs to screen YAC and BAC libraries for the construction of a contig for this region. A preliminary physical map based on clones isolated thus far confirms the marker order we determined using the Stanford G3 RH panel.

Allelic Loss and the Progression of Breast Cancer¹Diane M. Radford,² Nancy J. Phillips, Keri L. Fair, Jon H. Ritter, Matthew Holt, and Helen Donis-Keller

Division of Human Molecular Genetics, Department of Surgery [D. M. R., K. L. F., M. H., H. D.-K.] and Department of Pathology [J. H. R.], Washington University, St. Louis, Missouri 63110, and Department of Pathology, St. Louis University, St. Louis, Missouri 63110 [N. J. P.]

Abstract

To study genetic changes and the evolution of breast cancer, we assayed for loss of heterozygosity (LOH) in 12 sets of synchronous carcinoma *in situ* (CIS) and invasive cancer, compared to normal control DNA. Microsatellite markers were used, which map to each nonacrocentric autosomal arm. Eight tumor sets demonstrated LOH of the same allele in both concurrent invasive cancer and ductal CIS, for a total of 18 chromosomal loci. Three of nine tumor sets showed LOH on 11p. In two of these sets, LOH was seen on 11p only in the invasive tumor, not the corresponding CIS. One of these tumors also exhibited allelic loss in the invasive tumor for 4 loci, all of which were retained in the noninvasive tumor. For two tumor sets, LOH was mirrored in matched ductal CIS, invasive tumor, and lymph node metastasis. The maintenance of LOH for certain loci throughout the stages of breast cancer suggests clonality of the cancer cells.

Introduction

Human solid tumors are believed to arise due to a multistep process involving the activation of oncogenes and the inactivation of tumor suppressor genes. This cascade of genetic events releases the cell from normal regulatory controls, and allows the formation of the malignant phenotype, followed by the development of invasion and metastasis. In certain cancers, a chronology for these events has been determined, such as in the transition from benign polyp to invasive cancer of the colorectum (1). Little is known about the events that are involved in the transition of CIS³ of the breast to invasive cancer. DCIS is a noninvasive carcinoma and is a precursor to invasion in some cases, although it is not an obligate precursor (2). The subtypes of DCIS (such as comedo, cribriform, solid, papillary, and micropapillary) differ in biological behavior. We have studied the allelic loss of chromosomal loci in DCIS (3-5) and have established that the chromosomal arms that show the most frequent allelic losses in DCIS are 8p, 13q, 16q, 17p, and 17q. Other authors have reported LOH in DCIS on chromosomes 11q, 2p, and 4q (6, 7). To determine which chromosomal loci are involved in breast cancer progression, we continued our studies on examples of synchronous CIS and adjacent invasive breast cancer and, when available, lymph node metastases.

Materials and Methods

Twelve samples of tumor and control were obtained; 10 from the archives of the Department of Pathology, St. Louis University, 1 from Jewish Hospital (St. Louis, MO) and 1 from Barnes Hospital (St. Louis, MO). Paraffin-embedded, formalin/alcohol-fixed material was archived between 1988 and 1993. In two of these cases, lymph nodes involved with metastatic tumor were

also obtained for LOH assay. The pathologists (N. J. P. and J. H. R.) determined the subtype of the DCIS component and its nuclear grade (high, intermediate, or low). A microdissection technique was used to separate invasive tumor from CIS and from adjacent normal stroma (3). Uninvolved lymph node DNA from the same patient was used as normal control. DNA was extracted as described previously (3). LOH was assayed using PCR of microsatellite markers. The markers used and their PCR conditions have been described (5). PCR products were separated on 3M urea denaturing polyacrylamide sequencing gels and were dried before exposure to Kodak XAR film. LOH was determined by a combination of visual inspection and scanning densitometry of the autoradiographs. The technique used for scanning densitometry is fully described in Ref. 5. A 3-fold difference in the relative allele intensity ratios between tumor DNA and normal DNA in an informative tumor normal pair was scored as LOH (allele 1/allele 2 in tumor compared to allele 1/allele 2 in normal).

Results

Of the 12 samples of CIS available for study, 7 were comedo, high nuclear grade DCIS (tumors 46, 47, 49, 50, 57, 58, and 69). Tumor 48 was of the cribriform subtype of DCIS, intermediate nuclear grade; tumor 55: cribriform, low nuclear grade; tumor 56: micropapillary, low nuclear grade; tumor 70 terminal duct CIS (a variety of CIS that has histological features that resemble both lobular and DCIS), high nuclear grade; and tumor 72: mixed variety of DCIS, intermediate nuclear grade. In all cases the invasive component was of the invasive ductal variety.

We studied chromosomal deletions by assaying for LOH using 48 microsatellite markers that map to 39 nonacrocentric autosomal arms. The data obtained are summarized graphically in Fig. 1. For a total of 18 chromosomal loci, LOH could be demonstrated in both the CIS and invasive component of the tumor. LOH was observed in both DCIS and invasive tumor for loci on 1p (1 of 8 informative tumor sets), 1q (1 of 7), 7q (2 of 4), 8p (2 of 5), 11p (1 of 9), 13q (2 of 5), 16q (3 of 7), 17p (2 of 5), 17q (2 of 8), 18p (1 of 4), 18q (2 of 8), and 22q (1 of 6). In tumor 47, LOH at loci on 7q and 17p was seen in DCIS and LNM; the invasive tumor could not be assayed due to insufficient sample. Similarly, for tumor 48, LOH was seen at locus *CD3D* (11q) for both DCIS and LNM. At several loci the LOH pattern in DCIS and invasive component was also mirrored in the LNM [e.g., loci *DIS165*, *APOA2*, and *NM23* (tumor 47) and loci *D16S266* and *D16S402* (tumor 48)].

The DNA from two cases (cases 46 and 49) showed LOH on 11p in the invasive tumor but not the DCIS component. Fig. 2 shows examples of LOH for these tumors. Examination of Fig. 2, A-C shows virtually complete loss of an allele in both the DCIS and the invasive component of tumor 46 for loci on 13q, 17p, and 22q. This indicates that the sample was carefully dissected and that stromal contamination is not obscuring LOH in the DCIS component. Fig. 2 D shows the pattern of allelic loss for the same tumor sample using a marker on 11p. Two alleles are seen in the DCIS; however, there is a great reduction of the signal from one allele in the invasive tumor. These data were confirmed by densitometry. The fold difference in integrated allele ratios between DCIS and normal for the marker *D11S861* was 1.42 for tumor 46 and 1.74 for tumor 49. These figures do not

Received 8/30/95; accepted 9/28/95.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a Veterans Administration RAG grant, an American Cancer Society Career Development Award, USARDC Grant DAMD-94-J-4293 (to D.M.R.), and by NIH Grants HG00469 and HG01066 (to H. D. K.).

² To whom requests for reprints should be addressed, at 9901 Wohl Hospital, 660 South Euclid Avenue, St. Louis, MO 63110.

³ The abbreviations used are: CIS, carcinoma *in situ*; DCIS, ductal CIS; LOH, loss of heterozygosity; LNM, lymph node metastases.

Chr.	46 DCIS	46 INV	50 DCIS	50 INV	47 DCIS	47 INV	47 LNM	48 DCIS	48 INV	48 LNM	49 DCIS	49 INV	55 DCIS	55 INV	56 DCIS	56 INV	57 DCIS	57 INV	58 DCIS	58 INV	59 DCIS	59 INV	70 DCIS	70 INV	72 DCIS	72 INV	Marker
1p																										D1S165	
1q																										APOA2	
2p																										TPO	
2q																										D2S128	
3p																										D3S1211	
3q																										D3S1314	
4p																										D4S403	
4q																										D4S426	
5p																										D5S392	
5q																										D5S429	
6p																										F13A1	
6q																										D6S225	
7p																										D7S481	
7q																										D7S461	
7q																										D7S466	
8p																										D8S262	
8p																										D8S265	
8p																										D8S511	
8q																										D8S373	
9p																										D9S157	
9q																										D9S214	
10p																										D10S172	
10q																										D10S109	
11p																										D11S861	
11q																										INT2	
11q																										CD3D	
12p																										D12S94	
12q																										D12S101	
13q																										D13S118	
14q																										D14S543	
15q																										D15S87	
16p																										D16S423	
16q																										D16S266	
16q																										D16S402	
17p																										D17S849	
17p																										D17S513	
17p																										CHRNBI	
17p																										TP53	
17q																										D17S579	
17q																										NM23	
18p																										D18S59	
18q																										D18S70	
19p																										D19S177	
19q																										APOC2	
20p																										D20S59	
20q																										D20S102	
21q																										D21S167	
22q																										IL2RB	
Subtype	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	
Nuclear Grade	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	

Fig. 1. Summary of LOH data for 10 sets of synchronous CIS and adjacent invasive cancer and for two sets of DCIS, invasive cancer, and lymph node metastasis. The chromosomal arm is listed on the left, the marker used is on the right, and tumor number is on the top. 0, no LOH; 1, LOH; 2, noninformative; INV, invasive carcinoma; LNM, lymph node metastasis; C, comedo subtype; R, cribriform; M, micropapillary; TD, terminal ductal; X, mixed; H, high nuclear grade; L, low nuclear grade; I, intermediate.

meet our criteria for scoring LOH. However, the fold differences for the corresponding invasive components were 5.0 and 19.7, respectively. Densitometry at the other loci showing LOH for tumor 46 confirmed a difference >3-fold in each case for both DCIS and invasive tumor, compared with normal control.

For tumor 49, the invasive cancer also exhibited allelic loss for loci on 1p, 3p, 6q, and 7q. In the matched DCIS sample, both alleles were retained. This tumor also showed LOH in the invasive component

using a 2q marker, but insufficient DNA was available to assay the DCIS. The fractional allelic loss (number of chromosomal arms showing LOH/total number of informative chromosomal arms) for the invasive component of tumor 49 was 0.63 (7 of 11). In every case where LOH of loci was observed in concurrent DCIS and invasion (and LNM), the same allele was lost. Tumors 50, 69, 70, and 72 did not show allelic loss for any locus examined, although for 3 of these tumors, 4 loci or less were studied. All LOH results were verified with repeat assays at least once.

Discussion

Inactivation of tumor suppressor genes plays a central role in the development of human cancer and their progression. In invasive breast carcinoma, LOH of loci on virtually every chromosome has been observed (8, 9), making it difficult to ascertain which genetic events are the most crucial in oncogenesis. Our allelotyping study has revealed that loci on 8p, 13q, 16q, 17p, and 17q are lost most frequently (>14%) in DCIS, implying that tumor suppressor genes near these loci are important in the early stages of breast cancer (5).

Circumstantial evidence that DCIS is a precursor lesion to invasive ductal carcinoma is based on three observations: (a) the frequent coexistence of DCIS and invasive cancer in the same breast (10); (b) the greatly increased risk of subsequent invasive breast cancer in women with biopsy-proven DCIS (11); and (c) the finding that when a local recurrence is seen after breast-conserving treatment of DCIS, there is a 50% chance that the recurrence will be of the invasive variety (12). DCIS is not an obligate precursor, however, and other possible pathways to invasion may exist, such as the *de novo* transition to malignancy of normal epithelium without an intervening noninvasive stage.

Studies of the molecular changes in DCIS and invasive breast cancer are few. Davidoff *et al.* (13) studied 6 examples of synchronous DCIS and invasive cancer for expression of p53 and found the same levels of protein expression in each tissue type. Expression of the oncogenes *c-erbB-2* and *c-myc* is also consistent between coexisting preinvasive and invasive breast cancer (14, 15). Zhuang *et al.* (6) studied allelic loss for two loci on 11q13 (*INT2* and *PYGM*). They found that for every case of DCIS that showed LOH ($n = 15$), loss of the same allele was seen in the corresponding invasive tumor (6). O'Connell *et al.* (7) studied four loci [*TPO* (2pter), *D4S192* (4q25-34), *D16S265* (16q21), and *D17S579* (17q21)] and found that 8 of 10 cases of DCIS shared LOH patterns with more advanced lesions for at least 1 of the 4 loci.

Our study provides information on 48 loci representing the 39 nonacrocentric autosomal arms. The data show that if allelic loss at a locus is found in the DCIS component, it persists in the synchronous invasive cancer and LNM. This indicates that, in those tumors where DCIS and invasive cancer are adjacent, the invasive component has arisen in all likelihood from the DCIS. Our data are in accord with the clonal expansion theory of Nowell (16), which states that tumors progress through the sequential acquisition of genetic and biological features. It should also be noted that this clonal expansion is seen for examples of comedo, micropapillary, and cribriform varieties of DCIS.

In two invasive cancers (tumors 46 and 49), LOH occurs on 11p but is absent in DCIS. Allelic loss on 11p has been reported to occur in 10-41% of invasive breast cancer (5, 8), although we have found it to be a very infrequent event in DCIS (1 of 32 tumors). This suggests that inactivation of tumor suppressor loci on 11p may be one of the features of the invasive phenotype. The difference in the LOH pattern for tumor 46 for the locus *D11S861*, when compared with the other loci shown in Fig. 2, A-C, suggests that there is a clone of cells in the




Fig. 2. A, B, and C, tumor 46. Loss of the same allele in both DCIS and invasive component for loci *D13S118* (13q), *CHRNBI* (17p), and *IL2RB* (22q). The fold difference in integrated allele ratios between tumor and normal are: A, DCIS 4.12, invasive 7.25; B, DCIS 7.78, invasive 9.2; and C, DCIS 6.7, invasive 10.5. D, tumor 46. Loss of one allele in the invasive component but not DCIS for the locus *D11S861* (11p). The fold differences between tumor and normal are DCIS, 1.42 (insufficient to call LOH) and invasive, 5.0 (LOH). E and F, tumor 49. Loss of an allele in the invasive component but not DCIS for loci *D3S1211* (3p) and *D11S861* (11p). The fold difference in integrated allele ratios between tumor and normal are E, DCIS 1.95, invasive 9.7; F, DCIS 1.74, invasive 19.7.

invasive tumor that retains two 11p alleles, although the majority of these cells have lost one allele. In contrast, the loss of one allele is virtually complete in both DCIS and invasive component for this tumor at the other loci shown. According to the theory of Nowell, this suggests that LOH on 11p may be a later event chronologically in the pathway to invasion.

LOH on 11p has been correlated with low estrogen receptor protein and tumor size in invasive breast cancer, both of which are indicators of poorer prognosis (17). Concordant loss of 11p and 17p in invasive breast cancer is more frequently associated with the development of lymph node metastases (18). One invasive cancer (tumor 49) also showed loss of loci on 1p, 2q, 3p, 6q, 7q, and 17p, whereas the corresponding DCIS displayed loss only at the locus on 17p. Loss at all these sites has been reported for invasive breast cancer (8, 9) and may indicate a more aggressive phenotype. For example, LOH on 1p has been correlated with the

presence of lymph node metastases, larger tumor size, and non-diploidy (19), and LOH of loci on 7q with impaired survival (20). The high fractional allelic loss of the invasive component of tumor 49 suggests that multiple genetic events have taken place in this tumor.

In summary, these data suggest that the subtypes of DCIS represent precursor lesions of invasive ductal carcinoma of the breast. LOH of regions most commonly involved in DCIS (8p, 13q, 16q, 17p, and 17q) is maintained in the concurrent invasive component. Loss of alleles at other loci such as 11p may be later events which are a feature of the invasive phenotype.

Acknowledgments

The collaboration of the following individuals is appreciated: S. Scholnik (Department of Otolaryngology, Washington University) for helpful advice.

V. Herrmann (Department of Surgery, St. Louis University) and M. E. Schuh (Parkcrest Surgical Associates) for access to clinical information; T. and M. Christ for their generous financial donation; and Monsanto Company for matching that donation.

References

1. Fearon, E. R., and Jones, P. A. Progressing towards a molecular description of colorectal cancer development. *FASEB J.*, 6: 2783-2790, 1992.
2. Rogers, L. W. Carcinoma *in situ* (CIS). In: D. L. Page and T. J. Anderson (eds.), *Diagnostic Histopathology of the Breast*, pp. 157-192. Edinburgh: Churchill Livingstone, 1987.
3. Radford, D. M., Fair, K., Thompson, A. M., Ritter, J. H., Holt, M. S., Wallace, M. W., Wells, S. A., Jr., and Donis-Keller, H. R. Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res.*, 53: 2947-2950, 1993.
4. Radford, D. M., Fair, K. L., Thompson, A. M., Ritter, J. H., Holt, M. S., Wells, S. A., and Donis-Keller, H. R. Chromosomal regions implicated in the development of breast cancer. *Surg. Forum*, 44: 502-504, 1993.
5. Radford, D. M., Fair, K. L., Phillips, N. J., Ritter, J. H., Steinbrueck, T., Holt, M. S., and Donis-Keller, H. R. Allelotyping of ductal carcinoma *in situ* (DCIS) of the breast: deletion of loci on 8p, 13q, 16q, 17p, and 17q. *Cancer Res.*, 55: 3399-3405, 1995.
6. Zhuang, Z., Merino, M. J., Chuaqui, R., Liotta, L., and Emmert-Buck, M. R. Identical allelic loss on chromosome 11q13 in microdissected *in situ* and invasive breast cancer. *Cancer Res.*, 55: 467-471, 1995.
7. O'Connell, P., Pekkeli, V., Fuqua, S., Osborne, C. K., and Allred, D. C. Molecular genetic studies of early breast cancer evolution. *Breast Cancer Res. Treat.*, 32: 5-12, 1994.
8. Devilee, P., van Vliet, M., van Sloun, P., Kuipers-Dijkshoorn, N., Hermans, J., Pearson, P. L., and Cornelisse, C. J. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. *Oncogene*, 6: 1705-1711, 1991.
9. Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., and Nakamura, Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res.*, 50: 7184-7189, 1990.
10. Alpers, C. E., and Wellings, S. R. The prevalence of carcinoma *in situ* in normal and cancer-associated breasts. *Hum. Pathol.*, 16: 796-807, 1985.
11. Dupont, W. E., and Page, D. L. Risk factors for breast cancer in women with proliferative breast disease. *N. Engl. J. Med.*, 312: 146-151, 1985.
12. Solin, L. J., Recht, A., Fourquet, A., Kurtz, J., Kuske, R., McNeese, M., McCormick, B., Cross, M. A., Schultz, D. J., Bornstein, B. A., Spitalier, J.-M., Vilcoq, J. R., Fowble, B. L., Harris, J. R., and Goodman, R. L. Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma *in situ*) of the breast. *Cancer (Phila.)*, 68: 2337-2344, 1991.
13. Davidoff, A. M., Kerns, B., Iglehart, J. D., and Marks, J. R. Maintenance of p53 alterations throughout breast cancer progression. *Cancer Res.*, 51: 2605-2610, 1991.
14. Maguire, H. C., Jr., Hellman, M. E., Greene, M. I., and Yeh, I. Expression of *c-erbB-2* in *in situ* and in adjacent invasive ductal adenocarcinoma of the female breast. *Pathobiology*, 60: 117-121, 1992.
15. Watson, P. H., Safneck, J. R., Le, K., Dubik, D., and Shiu, R. P. Relationship of *c-myc* amplification to progression of breast cancer from *in situ* to invasive tumor and metastasis. *J. Natl. Cancer Inst.*, 85: 902-907, 1993.
16. Nowell, P. The clonal evolution of tumor cell populations. *Science (Washington DC)*, 194: 23-28, 1976.
17. Mackay, J., Elder, P. A., Porteous, D. J., Steel, C. M., Hawkins, R. A., Going, J. J., and Chetty, U. Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor level. *Br. J. Cancer*, 58: 710-714, 1988.
18. Takika, K., Sato, T., Miyagi, M., Watatani, M., Akiyama, F., Sakamoto, G., Kasumi, F., Abe, R., and Nakamura, Y. Correlation of loss of alleles on the short arm of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. *Cancer Res.*, 52: 3914-3917, 1992.
19. Borg, A., Zhang, Q., Olsson, H., and Wengren, E. Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. *Genes Chromosomes & Cancer*, 5: 311-320, 1992.
20. Bieche, I., Champeme, M. H., Matifas, F., Hacene, K., Callahan, R., and Lidereau, R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. *Lancet*, 339: 139-143, 1992.

Allelotyping of Ductal Carcinoma *in Situ* of the Breast: Deletion of Loci on 8p, 13q, 16q, 17p and 17q¹

Diane M. Radford,² Keri L. Fair, Nancy J. Phillips, Jon H. Ritter, Todd Steinbrueck, Matthew S. Holt, and Helen Donis-Keller

Division of Human Molecular Genetics, Department of Surgery [D. M. R., K. L. F., T. S., M. S. H., H. D.-K.] and Department of Pathology [J. H. R.], Washington University, St. Louis, Missouri 63110, and Department of Pathology, St. Louis University, St. Louis, Missouri 63110 [N. J. P.]

ABSTRACT

In order to determine which tumor suppressor loci are involved in preinvasive breast cancer, we have assayed for loss of heterozygosity (LOH) in ductal carcinoma *in situ* (DCIS). Areas of DCIS were microdissected from archival paraffin-embedded tissue. DNA was extracted, and LOH was determined by PCR of microsatellite markers that map to 39 autosomal arms. Either uninvolved lymph node or white cell DNA was used as normal control. A total of 61 samples of DCIS were assayed. The average number of informative tumors examined for each marker was 19 (range, 8-48). The median fractional allelic loss was 0.037. The highest percentage of LOH was shown for loci on 8p (18.7%), 13q (18%), 16q (28.6%), 17p (37.5%), and 17q (15.9%). LOH on 18q was found in 10.7% of informative tumors. Fractional allelic loss was associated with LOH on 17p, with high nuclear grade and with the comedo subtype of DCIS. LOH on 17p correlated with LOH on 17q and on 13q. Additional markers were used for 16q and 17p to determine the smallest common region of deletion. These data provide evidence that tumor suppressor loci that map to these regions are involved in the oncogenesis of breast cancer before progression to the invasive phenotype. Our findings provide additional support that multiple loci on 17p and 16q are involved in the development of breast cancer.

INTRODUCTION

DCIS³ of the breast is a preinvasive form of breast cancer in which malignant cells have not penetrated the basement membrane (1). The histopathological diagnosis encompasses a heterogeneous group of subtypes, including comedo, cribriform, solid, papillary and micropapillary, some of which may differ in biological behavior. The potential for associated microinvasion and likelihood of recurrence after breast conservation therapy are higher with the comedo subtype (2, 3). As with invasive breast cancer, DCIS can also be stratified by nuclear grade: high, intermediate, and low. A large number of articles have been published on LOH in invasive breast cancer, and virtually every human chromosome has been shown to exhibit allelic loss (4, 5). The most frequent losses are seen on chromosome 7q (0-83%) (4, 6, 7), 16q (32-63%) (4, 5, 8-10), 17p (31-75%) (4, 5, 11-14), 17q (24-79%) (4, 5, 15-21) and 18q (24-69%) (4, 18, 22, 23). Less frequent losses are found on 1p (3-47%) (4, 5, 24), 1q (16-32%) (4, 5, 25, 26), 3p (11-47%) (4, 5, 13), 6q (9-48%) (4, 5), 8p (27-33%) (4, 12), 11p (10-41%) (4, 27), and 13q (16-40%) (5, 13). Tumor suppressor genes thought to be involved in breast cancer include the *p53* gene at 17p13.1 (27, 28), *Rb* on 13q (5, 13) and *DCC* on 18q (22, 23). Recently, Schott *et al.* (29) have discovered another gene on 13q proximal to *Rb* (*Brush-1*), which is located within the 6-cM region

containing the inherited early onset breast cancer gene *BRCA-2*, located at 13q12-13 (30). A region telomeric to *p53* at 17p13.3 is also lost frequently in invasive breast cancer and is believed to harbor a separate tumor suppressor locus (31, 32). Several genes located on 17q are implicated in breast cancer oncogenesis, such as the recently cloned *BRCA-1* gene at 17q21 (33, 34) and the metastasis suppressor gene *NM23*, distal to *BRCA-1* (16, 17, 35). Because of the multiple putative tumor suppressor loci, which exhibit LOH in invasive breast cancer, it is not clear which loci are involved in oncogenesis and which are lost randomly due to the instability conferred by the malignant state of the genome.

The chronology of genetic changes leading to invasion has been elucidated for certain cancers, such as the transition from neoplastic polyp to colon carcinoma (36, 37), but has not been established for breast cancer. Our study is the first reported allelotype of DCIS and expands our knowledge of the genetic events leading to invasion in breast cancer.

MATERIALS AND METHODS

Subjects

A total of 61 women with the diagnosis of DCIS were entered into the study. Archival paraffin-embedded material for 57 cases was collected from the pathology department of several hospitals in St. Louis: Barnes Hospital, Jewish Hospital, Deaconess Hospital, St. Louis University Hospital, and the Outpatient Surgery Center, Inc. (St. Louis, MO). Data on 4 patients were provided by A. M. Thompson of the University of Edinburgh. Either matched archival normal lymph node DNA or leukocyte DNA was used as control. Examples of DCIS were categorized by the pathologists (J. H. R., N. J. P., K. DeSchuyver, and R. Brangle). When it was necessary to draw blood for normal control, informed consent was obtained following Institutional Review Board approval. Histological subtype and nuclear grade were: 42 comedo, 3 solid, 2 micropapillary, 1 papillary, 10 cribriform, and 3 mixed; 45 high nuclear grade, 14 low nuclear grade, and 2 intermediate.

Microdissection, DNA Purification, and Allelotyping

Tumor microdissection, DNA purification, and buffers for allelotyping have been described previously (38). The microsatellite markers used for these experiments are listed in Table 1. The PCR conditions for these markers was as follows all denaturation steps were at 94°C for 1 min and the majority of extension steps were performed at 72°C for 1 min. Annealing temperature ranged from 52 to 64°C, annealing time, from 30 s to 2 min, and number of cycles ranged from 22 to 30. The majority of markers chosen had a heterozygosity $\geq 70\%$. LOH was determined by a combination of naked-eye assessment and scanning densitometry. The tumors scored as showing LOH by visual inspection were subjected to densitometry. Densitometry was performed by scanning autoradiographs with a UMEX UC630 color scanner and with the use of the software program Adobe Photoshop 2.5.1 (Adobe Systems, Inc.). The densitometry histograms were analyzed on a Power Macintosh 6100/60 with the use of the public domain NIH image program (written by Wayne Rasband, NIH; available from the Internet by anonymous FTP from zippy.nimh.nih.gov.). A 3-fold difference in the relative allele intensity ratios between tumor DNA and normal DNA in an informative tumor normal pair was scored as LOH (allele 1/allele 2 in tumor compared to allele 1/allele 2 in normal). We have performed admixture experiments with the use of the DNA from two homozygous individuals and have established that LOH can be determined by the naked eye provided that

Received 1/31/95; accepted 5/31/95.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a Veterans Administration RAG grant and an American Cancer Society Career Development award (D.M.R.) and in part by NIH Grants HG00469 and HG01066-01A1 (H.D.K.).

² To whom requests for reprints should be addressed, at 9901 Wohl Hospital, 660 S. Euclid Avenue, St. Louis, MO 63110.

³ The abbreviations used are: DCIS, ductal carcinoma *in situ*; GDB, Genome Database; FAL, fractional allelic loss; LOH, loss of heterozygosity; CEPH, Centre d'Etude Polymorphisme Humain.

"contamination" does not exceed 20% (data not shown). Samples with marginal allele reduction by inspection were not scored as LOH; thus, our method of scoring is conservative.

LOH on Chromosome 17

The markers used previously (38, 39) and two additional markers, *D17S578* and *D17S849*, were applied to a panel of 61 examples of DCIS.

Statistical Analysis

Statistical analysis was performed with the use of contingency tables and the unpaired *t* test with the software package Statview (Abacus Industries, Berkeley, CA). The null hypothesis for each analysis was that the two variables were independent of each other. At the 0.05 level of significance the null hypothesis was rejected.

Genetic Map Construction

Chromosome 17p. Nineteen loci were incorporated into a linkage map for a portion of the short arm of chromosome 17. Five microsatellite markers (*c1541/D17S260*, *AFM234wg3a3m/D17S849*, *Mfd152/D17S578*, *ut20/D17S654*, and *ut269/D17S695*) were not part of our previous 17p map (38). Genotypes for *D17S513* (12G6), *D17S260* (c1541), *D17S578* (Mfd152), *D17S849* (AFM234wg3a3m), *CHRNA1* (IMG4125/26), *D17S379* (DL1), *TP53* (TP53CA), *D17S643* (ut18), *D17S654* (ut20), and *D17S695* (ut269) were produced in our laboratory with the use of the CEPH 40 family reference pedigrees. Genotypic data for *D17S31* (pMCT35.1*Msp*I and pMCT35.2*Msp*I), *D17S28* (pTB7c-2.1), *D17S30* (pYNZ22*Rsa*I), *D17S499* (cLS17.6*Pvu*II), *D17S510* (fLB17.3*Alu*I), *D17S505* (fLB17.8*Alu*I), *D17S506* (fLB17.9*Pst*I), *MYH2* (p10.5*Hind*III), and *D17S34* (p144-D6*Rsa*I) were obtained from the CEPH database (version 6). Oligonucleotide primer sequences and reaction conditions for ut markers were obtained from the Utah Genome Center (40), and several of these have since been published (41). PCR primer sequences and reaction conditions for *D17S379* were provided by Dr. D. Ledbetter and have subsequently become accessible via GDB (42). In our previous paper it was arbitrarily referred to as DL1 because it had not been published at that time (39). Primer sequences and reaction conditions for the other markers used in the map are available from the GDB (<http://gdbwww.gdb.org>). The CRIMAP program package was used to construct the map with odds for loci order of at least 1000:1. "flips4" permutations of marker order was used to test for the most likely order with the use of data from the "build" analysis. Two additional markers from chromosome 17, ut9, and ut69 (made available from the Utah Genome Center) were also genotyped in this study, but two-point analysis indicated that they mapped to 17q, and they were not studied further.

Sixteen of the 19 loci, including all 9 markers used for the LOH analysis, were uniquely placed with odds for order of at least 1000:1. The sex average map extends a total of 47.1 cM. *CHRNA1* has now been uniquely localized at 1000:1 odds, whereas in a map reported previously the odds were less than 50:1 (39). Genotypes used to construct the chromosome 17p map, map graphics, and associated data reported here are available through the GenLink resource (<http://www.genlink.wustl.edu>).

Chromosome 16. A human chromosome 16 linkage map constructed previously, which included all 11 markers used for our LOH analysis was available from the Cooperative Human Linkage Center along with the genotypic data from the CEPH database (version 6; Ref. 43; <ftp.chlc.org>). We used the "fixed" option of CRIMAP to calculate the genetic distances between the markers and the "all" option to verify the placement of 3 nonuniquely placed markers (*D16S423*, *D16S405*, and *D16S261*). It is apparent that *D16S423* is the most distal 16p marker used for LOH studies and that *D16S405* is the penultimate LOH marker. Nonuniquely localized LOH marker *D16S261* is flanked by LOH markers *D16S403* and *D16S541* on the linkage map.

Cytogenetic Tie Points. All physical localizations that tie the genetic to the cytogenetic maps for chromosomes 16 and 17 were taken from information available from the GDB.

RESULTS

Allelotyping. A total of 61 microdissected cases of DCIS were assayed for LOH with the use of a panel of microsatellite markers

Table 1 Polymorphic markers and percentage LOH observed in DCIS allelotyping. The combined LOH for markers on 16p was 1 of 19 (5.2%), 16q 8 of 28 (28.6%), and 17p 18 of 48 (37.5%)

Chromosome	Marker	LOH (%)
1p36	<i>D1S165</i>	1/24 (4.1)
1q21-23	<i>APOA2</i>	0/23
2p25-24	<i>TPO</i>	0/19
2q33-37	<i>D2S128</i>	1/23 (4.3)
3p24.2-22	<i>D3S1211</i>	2/28 (7.1)
3q27	<i>D3S1314</i>	0/17
4p	<i>D4S403</i>	0/8
4q	<i>D4S426</i>	0/9
5p	<i>D5S392</i>	0/19
5q	<i>D5S429</i>	0/18
6p24.2-23	<i>F13A1</i>	0/10
6q21-23.3	<i>D6S225</i>	2/22 (9.0)
7pter-p15	<i>D7S481</i>	0/16
7q	<i>D7S466</i>	1/24 (4.2)
8p23	<i>D8S262</i>	3/16 (18.7)
8q	<i>D8S373</i>	0/23
9p23-22	<i>D9S157</i>	0/14
9q34.1	<i>D9S214</i>	0/15
10p	<i>D10S172</i>	0/17
10q11.2-qter	<i>D10S109</i>	0/12
11p15.2	<i>D11S861</i>	0/31
11q23.3	<i>CD3D</i>	1/4 (7.1)
12p13	<i>D12S94</i>	0/17
12q14-24.33	<i>D12S101</i>	0/13
13q14.1	<i>D13S118</i>	4/22 (18)
14q	<i>D14S543</i>	1/16 (6.3)
15q	<i>D15S87</i>	0/21
16p13.3	<i>D16S423</i>	0/15
16p13.1	<i>D16S405</i>	1/8 (12.5)
16p12	<i>D16S403</i>	0/13
16q12.1	<i>D16S261</i>	3/13 (23)
16q12.1	<i>D16S541</i>	3/10 (30)
16q12.1-12.2	<i>D16S415</i>	3/14 (21.4)
16q21	<i>D16S265</i>	3/23 (13)
16q23	<i>D16S266</i>	2/8 (25)
16q24.2	<i>D16S402</i>	5/20 (25)
16q24	<i>D16S539</i>	4/12 (33.3)
16q24.3	<i>D16S413</i>	4/19 (21)
17p	<i>D17S643</i>	3/22 (13.6)
17p	<i>D17S849</i>	5/14 (35.7)
17p	<i>D17S379</i>	3/17 (17.6)
17p	<i>D17S513</i>	13/34 (38.2)
17p	<i>D17S578</i>	1/10 (10)
17p	<i>CHRNA1</i>	6/20 (30)
17p13.1	<i>TP53</i>	8/26 (30.7)
17q11.2-12	<i>D17S250</i>	1/13 (7.7)
17q	<i>D17S579</i>	4/38 (10.5)
17q21-22	<i>NM23</i>	2/16 (12.5)
18pter-11.22	<i>D18S59</i>	1/17 (5.8)
18q23	<i>D18S70</i>	3/28 (10.7)
19p13.3	<i>D19S177</i>	0/12
19q13.2	<i>APOC2</i>	0/14
20p	<i>D20S59</i>	0/11
20q13	<i>D20S102</i>	0/11
21q22.2	<i>D21S167</i>	1/16 (6.3)
22q13	<i>IL2RB</i>	1/19 (5.2)

mapping to 39 non-acrocentric autosomal arms. Frequency of LOH is summarized in Table 1 and depicted graphically in Fig. 1. Examples of loci exhibiting LOH are shown in Fig. 2. The average number of informative loci/tumor was 19 (range, 8-48). Range of percentage LOH was from 0 to 37.5 with a mean of 5.2%. Significant LOH was arbitrarily chosen to be a value above the mean (or background) percentage LOH plus 1 SD. Chromosomal arms that showed LOH >14% were 8p (18.7%), 13q (18%), 16q (28.6%), 17p (37.5%), and 17q (15.9%). LOH on 18q was found in 10.7% of informative cases. **FAL**, defined as the number of arms showing allelic loss divided by the total number of informative arms/tumor, was calculated for a total of 24 tumors with 15 or more informative arms (44, 45). The range of FAL was from 0.00 to 0.333 with a median of 0.037 and a mean of 0.063.

The unpaired *t* test and contingency tables were used to determine if there was any significant correlation among variables such as LOH




Fig. 1. DCIS allelotype. □, p arm; ■, q arm.

on 17p, 17q, 16q, 13q, and 8p, nuclear grade, subtype (comedo *versus* noncomedo) and FAL. Due to the small sample size, the subtypes were not statistically evaluated separately. Significant associations were found between LOH on 17p and LOH on 17q ($P = 0.006$), LOH on 17p and LOH on 13q ($P = 0.0055$), and LOH on 17p and FAL greater than median ($P = 0.0038$). The mean FAL for comedo tumors was 0.087 *versus* 0.016 for noncomedo tumors ($P = 0.0326$), and the mean FAL for tumors of high nuclear grade was higher than those of low nuclear grade ($P = 0.0338$).

LOH on Chromosome 17. Fig. 3 depicts the LOH data for chromosome 17 with the use of a panel of 53 tumors. Of a total of forty-eight 17p arms, for which markers were informative, LOH was seen in 18 (37.5%). In three tumors, the deletion appeared to involve the entire short arm (numbers 19, 23, and 41), and this may also be the case for tumors 46 and 47. In tumor 11 the deletion did not extend to the most telomeric marker *D17S643* (ut18). Tumor 1 exhibits two separate areas of deletion, one encompassing the *TP53* and *CHRNBI* loci and the other extending from *D17S513* to *D17S849*, with retention of the intervening locus *D17S578*. Three tumors showed a smaller deletion: in tumor 27, the only locus showing loss was *D17S513*; tumor 38 had LOH at *D17S849*; and tumor 39 had a loss of an allele at *TP53*. Tumor 10 had deletion at the *D17S513* locus with retention of *TP53*. The two smallest common regions of deletion on 17p are depicted by vertical lines on the right of Fig. 3. One region measuring 11.6 cM encompasses the markers *D17S849* through *D17S379* at 17p 13.3, and its boundaries are established by the deletion pattern seen in tumors 1 and 38. The other deleted region is localized to 17p 13.1 and includes the *TP53* locus and *D17s31* and measures 3.4 cM.

For loci on the long arm (*D17S250*, *D17S579*, and *NM23*), a total of 44 arms were informative with LOH being seen on 7 (15.9%). For the individual loci, LOH was as follows: *D17S250*, 1 of 13 (7.6%); *D17S579*, 4 of 38 (10.5%); and *NM23*, 2 of 16 (12.5%). Both *D17S250* and *D17S579* are linked with the hereditary early-onset breast cancer gene *BRCA-1* (33). The combined LOH for these two markers was 5 of 40 (12.5%).

LOH on Chromosome 16. Fig. 4 shows the cumulative data for LOH on chromosome 16 with the use of the markers listed in Table 1. Allelic loss was found in 8 of 28 q arms for which markers were informative (28.6%). In 3 tumors the deletion was large (tumors 4, 19, and 23); however, in 3 tumors a smaller deletion was seen. In tumor

2 only the *D16S413* locus was lost; in tumor 38 only the *D16S402* locus was lost. The full extent of the deletion in tumor 48 cannot be determined currently as the markers flanking *D16S266* and *D16S402* were noninformative. The smallest common areas of deletion on 16q are shown by vertical lines. One region of deletion shown by tumor 20 includes the markers *D16S261* through *D16S415*. This region measures from 8.5 to 17.2 cM and is located at 16q12.1. A precise size cannot be given because *D16s261* is not uniquely placed on the map. This tumor also shows a separate region of deletion from *D16S402* distally. Tumors 20 and 2 limit the other common region of loss to a 26-cM distance below *D16S402* (at 16q24.2). All of the microsatellite markers used in the above experiments were tested on DNA from the CEPH reference panel to ensure that allele-specific amplification did not occur.

DISCUSSION

In our allelotyping study of DCIS we have shown that some of the earliest changes in the progression to malignancy in the breast are loss of alleles on 8p, 13q, 16q, 17p, and 17q. It is presumed that most solid tumors in humans arise through a cascade of genetic events involving oncogenes and tumor suppressor genes that results in decreasing stability of the genome and ultimately leads to the malignant phenotype. As additional mutations and/or deletions occur, these malignant cells may progress to invasion and later metastasis. The majority of LOH studies on breast cancer reported to date have concentrated on the invasive varieties of breast cancer and have found significant LOH on multiple chromosomal arms (4, 5). DCIS is a noninvasive precursor (though not an obligate precursor) of breast cancer (46) and, therefore, studies of allelic loss in this condition will help to determine which are some of the early events in oncogenesis. Our data indicate that the number of chromosomal arms that show LOH in DCIS is considerably fewer than in invasive cancer. This would be expected if one considers DCIS to be a preinvasive landmark on one of the pathways to invasion. The accumulation of additional mutations and deletions on other chromosomal regions may then result in the invasive phenotype.

Both 16q and 17p have been reported to harbor more than one tumor suppressor locus (8–11). On 17p one locus is the *TP53* gene at 17p13.1 with an additional independent locus situated more telomeric




Fig. 2. LOH at multiple loci in DCIS. For each autoradiograph the locus, the tumor number, and the fold-difference in integrated allele ratios between tumor and normal are listed: *D3S1211*, tumor 37, 4.8-fold; *D6S225*, tumor 23, 3-fold; *D13S118*, tumor 58, 5.2-fold; *D16S402*, tumor 19, 7.6-fold; *D16S265*, tumor 23, 4-fold; *TP53*, tumor 41, 4.1-fold; *D18S70*, tumor 37, 6.3-fold; *D18S70*, tumor 46, 4.3-fold. In each case PCR products from tumor (T) and normal (N) genomic DNA from an individual with DCIS are shown. The loss of one allele in the tumor lane is seen in all photographs. →, allele loss.

at 17q13.3 (18). Our deletion map of 17p supports the existing evidence for two separate loci. The isolated deletion of *D17S513* in tumor 27 raises the possibility of a third tumor suppressor locus on 17p. Similarly, in invasive breast cancer, three regions on 16q may contain the loci for tumor suppressor genes; one region near the telomere at 16q24.3, one at 16q22-23, and another at 16q21 (8-10). Our data also support the existence of multiple tumor suppressor loci on 16q that appear to be involved in the early stages of breast cancer. Two regions of loss are located at 16q12.1 and 16q24.2, respectively. Tumor 38 lost the *D16S402* marker at 16q24.2. One tumor also lost the most telomeric marker *D16S413*, at 16q24.3, but although the more proximal marker was noninformative, the extent of deletion in this tumor is unknown. We did not find an overlapping region of deletion at 16q21 as others have reported. The marker *D16S265*, which maps to this area, was informative in 23 cases and showed LOH in 3 of them (13%). Tumor 20 excludes this area from the common regions of deletion. Tsuda *et al.* (10) noted LOH at 16q12 in 36% of invasive breast cancers, with an overall rate of LOH on 16q of 52%. The highest rate of loss seen by these investigators was at 16q24.3. This group analyzed 27 cases of intraductal and predominantly intraductal cancers and found LOH on 16q in 8 of them (35%). It is not

stated how many of the tumors that showed LOH were purely intraductal without an invasive component.

LOH on 17q occurs in a large proportion of invasive breast cancer, both familial and sporadic (15, 18-21). At least three separate regions of deletion have been reported 17q12-21, 17q22-23, and 17q24-25 (15, 47). The hereditary early onset breast cancer gene *BRCA-1* at 17q21 has been identified recently (34) and appears to act as a tumor suppressor in inherited breast cancer. However, Futreal *et al.* (48) have found few mutations in the remaining *BRCA-1* allele in what was believed to be sporadic breast cancer. Of the 32 cases of invasive breast cancer that showed LOH of the *BRCA-1* region only, 3 patients had *BRCA-1* mutations in their tumors. All of these patients were found to have germline mutations. It has been suggested that the chromosomal deletions at 17q21 in sporadic breast cancer unmask another tumor suppressor locus distinct from *BRCA-1*. We found the frequency of allelic loss of loci linked to *BRCA-1* to be 12.5% in DCIS lesions (a figure which did not meet the value of 14%, which we considered to be significant). Another tumor suppressor locus, which may be unmasked by the usually large deletions of 17q found in invasive breast cancer, is *NM23* at 17q22 (35). *NM23* appears to be involved in both progression and metastasis of breast cancer (49).




Fig. 3. Sex average multipoint linkage map for distal 17p including cytogenetic tie points and cumulative data for chromosome 17 deletions observed in 53 DCIS tumors. Map, genetic loci uniquely placed with odds of at least 1000:1 are shown to the right of the vertical line of the linkage map and nonuniquely localized markers are shown to the left of the map line with the location intervals indicated by thin vertical bars. No recombinants were detected between D17S695 and D17S34 (p144-D6RsaI). Genetic distance in cM is given to the left of the linkage map line. Markers used for LOH studies are enclosed by a box. Genetic markers for which physical localizations were available are tethered to the cytogenetic map. D17S250, D17S579, and NM23 are located on 17q. LOH data: top, DCIS samples; bottom, DCIS subtype and nuclear grade. Genetic markers are listed in the order determined from the linkage map. ●, no loss; ○, LOH; ⊙, noninformative; H, high nuclear grade; L, low nuclear grade; I, intermediate nuclear grade; C, comedo; R, cribriform; S, solid; M, micropapillary; P, papillary; X, mixed. Horizontal lines within the diagram and vertical lines on the right, common areas of deletion. Tumors which limit these boundaries are marked with an *.




Fig. 4. Sex average multipoint linkage map for chromosome 16 and cumulative data for chromosome 16 deletions observed from 28 DCIS tumors. Marker designations are as indicated for Fig. 3. Nonuniquely and uniquely placed markers are on the right of the vertical line and genetic distances on the left. Abbreviations are the same as for Fig. 3. Vertical lines, common areas of loss.

In the past LOH assays on 13q in invasive breast cancer have concentrated on the region around the *Rb* gene at 13q14 (13). Recently, Schott *et al.* (29) have reported a separate tumor suppressor gene on 13q, *Brush-1*, which maps proximal to *Rb* at 13q12-13. They found that rates of LOH in invasive breast cancer at the *Rb* locus and at 13q13 were similar. A second hereditary breast cancer gene *BRCA-2* was recently mapped to 13q12 and *Brush-1* is contained within the 6 cM region containing *BRCA-2* (30). The marker we used for 13q, *D13S118*, maps to 13q14.1. Whether the *Brush-1* gene is inactivated in DCIS is yet to be determined.

Our data showed allelic loss in 18.7% of informative tumors at 8p23. LOH on 8p has been seen in several tumor types, including colorectal and hepatocellular carcinoma (50, 51). 8p also harbors at least two tumor suppressor loci which map to 8p23.1-pter and 8p21 respectively (50).

The relationship between FAL and clinical behavior of cancer was first noted by Kern *et al.* (45) who found FAL greater than the median in colorectal cancer to be associated with distant metastases (45). We have established that the median FAL in DCIS is 0.037. The FAL reported for invasive breast cancer is 0.05 (5). Our finding that the comedo subtype and high nuclear grade DCIS are associated with higher FAL may be correlated with the more aggressive clinical behavior of these phenotypes. Comedo high nuclear grade tumors are more likely to recur locally after resection and to progress to invasive cancer (52). They have a higher incidence of aneuploidy (53) and higher thymidine-labeling indices (54). Several authors have found that genetic abnormalities in breast cancer correlate with clinicopathological parameters. For example, LOH on 7q is associated with decreased survival (7). LOH at 17p13 and at 16q24.3 have been reported to be associated with more aggressive disease in invasive breast cancer (8, 55-57). In the accumulation of LOH which contributes to cancer formation, LOH of certain regions appear to act in a cooperative manner. In invasive breast cancer, LOH on 13q and 17p is associated as is LOH on 17p and 17q (13, 14). As Kern *et al.* (45) noted in colorectal cancer, we also found an association between FAL and LOH of 17p.

In summary, significant LOH occurs in DCIS for loci on 8p (18.7%), 13q (18%), 16q (28.6%), and 17p (37.5%), regions that also exhibit high rates of loss in invasive cancer. Our data imply that inactivation of tumor suppressor genes at these sites are early events in the tumorigenesis of breast cancer, and that LOH of other loci may be involved in progression and metastasis. Of note, even in this early noninvasive stage of breast cancer, at least 7 chromosomal regions, harboring tumor suppressor genes, are already implicated in oncogenesis. These data support the epidemiological hypothesis that from 3 to 8 genetic abnormalities must accumulate over time for malignancy to develop (58). We plan to refine further the regions of loss on 16q, 17p, and 8p with fine structure mapping and to apply positional cloning techniques to identify the tumor suppressor genes in these areas of interest.

ACKNOWLEDGMENTS

The collaboration of the following individuals is appreciated: Dr. R. Brangle (Department of Pathology, Deaconess Hospital) and Dr. K. DeSchraver (West Central Pathologists, Inc., St. Louis, MO) for providing specimens; S. Steinbrueck and L. Liu (Division of Human Molecular Genetics, Department of Surgery, Washington University) for computer support; Dr. S. Scholnick (Department of Otolaryngology, Washington University) for helpful advice, A. N. Thompson (Department of Surgery, University of Edinburgh) for providing data on 4 samples; Dr. M. E. Schuh (Parkcrest Surgical Associates) for access to clinical information; and T. and M. Christ for their generous financial donation and the Monsanto Company for matching the donation.

REFERENCES

- Broders, A. C. Carcinoma *in situ* contrasted with benign penetrating epithelium. *JAMA*, 99: 1670-1674, 1932.
- Lagios, M. D. Duct carcinoma *in situ*. In: *Breast Cancer: Strategies for the 1990s*. Surg. Clin. N. Am., 70: 853-871, 1990.
- Schnitt, S. J., Silen, W., Sadowsky, N. L., Connolly, J. L., and Harris, J. R. Ductal carcinoma *in situ* (intraductal carcinoma) of the breast. *N. Engl. J. Med.*, 318: 898-903, 1988.
- Devilee, P., van Vliet, M., van Sloun, P., Kuipers-Dijkshoorn, N., Hermans, J., Pearson, P. L., and Cornelisse, C. J. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. *Oncogene*, 6: 1705-1711, 1991.
- Sato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., and Nakamura, Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. *Cancer Res.*, 50: 7184-7189, 1990.
- Zenklusen, J. C., Bieche, I., Lidereau, R., and Conti, C. J. (C-A)n microsatellite repeat D7S22 is the most commonly deleted region in human primary breast cancer. *Proc. Natl. Acad. Sci. USA*, 91: 12155-12158, 1994.
- Bieche, I., Champene, M. H., Matifas, F., Hacene, K., Callahan, R., and Lidereau, R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. *Lancet*, 339: 139-143, 1992.
- Lindblom, A., Rotstein, S., Skoog, L., Nordenskjold, M., and Larsson, C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. *Cancer Res.*, 53: 3707-3711, 1993.
- Cleton-Jansen, A., Moerland, E. W., Kuipers-Dijkshoorn, N. J., Callen, D. F., Sutherland, G. R., Hansen, B., Devilee, P., and Cornelisse, C. J. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. *Genes, Chromosomes & Cancer*, 9: 101-107, 1994.
- Tsuda, H., Callen, D. F., Fukutomi, T., Nakamura, Y., and Hirohashi, S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespective of differences in phenotype and extent of spread. *Cancer Res.*, 54: 513-517, 1994.
- Lindblom, A., Skoog, L., Andersen, T. I., Rotstein, S., Nordenskjold, M., and Larsson, C. Four separate regions on chromosome 17 show loss of heterozygosity in familial breast cancers. *Hum. Genet.*, 91: 6-12, 1993.
- Lindblom, A., Skoog, L., Rotstein, S., Werelius, B., Larsson, C., and Nordenskjold, M. Loss of heterozygosity in familial breast carcinomas. *Cancer Res.*, 53: 4356-4361, 1993.
- Andersen, T. I., Gaustad, A., Ottestad, L., Farrants, G., Nesland, J. M., Tveit, K., and Borresen, A. L. Genetic alterations of the tumor suppressor gene regions 3p, 11p, 13q, 17p and 17q in human breast carcinomas. *Genes, Chromosomes & Cancer*, 4: 113-121, 1992.
- Sato, T., Akiyama, F., Sakamoto, G., Kasumi, F., and Nakamura, Y. Accumulation of genetic alterations and progression of primary breast cancer. *Cancer Res.*, 51: 5794-5799, 1991.
- Cropp, C. S., Champene, M., Lidereau, R., and Callahan, R. Identification of three regions on chromosome 17q in primary human breast cancer which are frequently deleted. *Cancer Res.*, 53: 5617-5619, 1993.
- Cropp, C. S., Lidereau, R., Leone, A., Liscia, D., and Cappa, A. P. NME1 protein expression and loss of heterozygosity in primary human breast tumors. *J. Natl. Cancer Inst.*, 86: 1167-1169, 1994.
- Caligo, M. A., Ghimenti, C., and Bevilacqua, G. NM23.H1 loss of heterozygosity in human mammary carcinomas. *Ann. NY Acad. Sci.*, 698: 136-142, 1993.
- Cropp, C., Lidereau, R., Campbell, G., Champene, H., and Callahan, R. Loss of heterozygosity on chromosomes 17 and 18 in breast cancer: two additional regions identified. *Proc. Natl. Acad. Sci. USA*, 87: 7737-7741, 1990.
- Saito, H., Inazawa, J., Saito, S., Kasumi, F., Koi, S., Sagae, S., Kudo, R., Saito, J., Noda, K., and Nakamura, Y. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. *Cancer Res.*, 53: 3382-3385, 1993.
- Borg, A., Zhang Q., Johannsson O., and Olsson H. High frequency of allelic imbalance at the *BRCA 1* region on chromosome 17q in both familial and sporadic ductal breast carcinomas. *J. Natl. Cancer Inst.*, 86: 792-794, 1994.
- Futreal, P. A., Soderkvist, P., Marks, J. R., Iglehart, J. D., Cochran, C., Barrett, J. C., and Wiseman, R. W. Detection of frequent allelic loss on proximal 17q in sporadic breast carcinoma using microsatellite length polymorphisms. *Cancer Res.*, 52: 2624-2627, 1992.
- Thompson, A. M., Morris, R. G., Wallace, M., Wylie, A. H., Steel, C. M., and Carter, D. C. Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. *Br. J. Cancer*, 68: 64-68, 1993.
- Devilee, P., van Vliet, M., Kuipers-Dijkshoorn, N., Pearson, P. L., and Cornelisse, C. J. Somatic genetic changes on chromosome 18 in breast carcinomas: is the *DCC* gene involved? *Oncogene*, 6: 311-315, 1991.
- Bieche, I., Champene, M.-H., Matifas, F., Cropp, C., Callahan, R., and Lidereau, R. Two distinct regions involved in 1p deletion in human primary breast cancer. *Cancer Res.*, 53: 1990-1994, 1993.
- Chen, L., Kurisu, W., Ljung, B., Goldman, E. S., Moore, D., and Smith, H. S. Heterogeneity for allelic loss in human breast cancer. *J. Natl. Cancer Inst.*, 84: 506-510, 1992.
- Chen, L.-C., Dollbaum, C., and Smith, H. S. Loss of heterozygosity on chromosome 1q in human breast cancer. *Proc. Natl. Acad. Sci. USA*, 86: 7204-7207, 1989.
- Deng, G., Chen, I.-C., Schott, D. R., Thor, A., Bhargava, V., Ljung, B., Chew, K., and Smith, H. S. Loss of heterozygosity and *p53* mutations in breast cancer. *Cancer Res.*, 54: 499-505, 1994.
- Thompson, A. M., Anderson, T. J., Condie, A., Prosser, J., Chetty, U., Carter, D. C., Evans, H. J., and Steel, C. M. *p53* allelic losses, mutations and expression in breast

- cancer and their relationship to clinicopathologic parameters. *Int. J. Cancer*, 50: 528-532, 1992.
29. Schott, D. R., Chang, J. N., Deng, G., Kurisu, W., Kuo, W.-L., Gray, J., and Smith H. S. A candidate tumor suppressor gene in human breast cancers. *Cancer Res.*, 54: 1393-1396, 1994.
30. Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., Fields, P., Marshall, G., Narod, S., Lenoir, G. M., Lynch, H., Fuentun, J., Devilee, P., Cornelisse, C., Menko, F., Daly, P., Ormiston, W., McManus, R., Pye, C., Lewis, C., Cannon-Albright, L., Peto, J., Ponder, B., Skolnick, M. H., Easton, D., Goldgar, D., and Stratton, M. Localization of a breast cancer susceptibility gene, *BRCA2* to chromosome 13q12-13. *Science* (Washington DC), 265: 2088-2090, 1994.
31. Cornelis, R. S., van Vliet, M., Vos, C. B., Cleton-Jansen, A., van de Vijer, M., Peterse, J., Khan, P. M., Borrensen, A., Cornelisse, C., and Devilee, P. Evidence for a gene on 17p13.3, distal to tp53, as a target for allele loss in breast tumors without p53 mutations. *Cancer Res.*, 54: 4200-4206, 1994.
32. Coles, C., Thompson, A. M., Elder, P. A., Cohen, B. B., Mackenzie, I. M., Cranston, G., Chetty, U., Mackay, J., Macdonald, M., Nakamura, Y., Hoyheim, B., and Steel, C. M. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. *Lancet*, 336: 761-763, 1990.
33. Hall, J. M., Friedman, L., Guenther, C., Lee, M. K., Weber, J. L., Black, D. M., and King, M. C. Closing in on a breast cancer gene on chromosome 17q. *Am. J. Hum. Genet.*, 50: 1235-1242, 1992.
34. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bodgen, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P., Norris, F., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, C., Lewis, C., Neuhausen, S., Canon-Albright, L., Golgar, D., Wiseman, R., Kamb, A., and Skolnick, M. H. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* (Washington DC), 266: 66-71, 1994.
35. Steeg, P. S., Bevilacqua, G., Pozatti, R., Liotta, L., and Sobel, M. Altered expression of *NM23*, a gene associated with low tumor metastatic potential, during adenovirus 2 E1a inhibition of experimental metastasis. *Cancer Res.*, 48: 6550-6554, 1988.
36. Fearon, E. R., and Jones, P. A. Progressing towards a molecular description of colorectal cancer development. *FASEB J.*, 6: 2783-2790, 1992.
37. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. *Cell*, 61: 759-767, 1990.
38. Radford, D. M., Fair, K., Thompson, A. M., Ritter, J. H., Holt, M., Steinbrueck, T., Wallace, M., Wells, S. A., and Donis-Keller, H. R. Allelic loss on chromosome 17 in ductal carcinoma *in situ* of the breast. *Cancer Res.*, 53: 2947-2950, 1993.
39. Radford, D. M., Fair, K. L., Thompson, A. M. *et al.* Chromosomal regions implicated in the development of breast cancer. *Surg. Forum*, XLIV: 502-504, 1993.
40. Fain, P. R. Report of the third international workshop on human chromosome 17 mapping. *Cytogenet. Cell Genet.*, 60: 177-186, 1992.
41. Gerken, S. C., Albertsen, H., Elsner, T., Ballard, L., Holik, P., Lawrence, E., Moore, M., Zhao, X., and White, R. A strategy for constructing high-resolution genetic maps of the human genome: a genetic map of chromosome 17p, ordered with meiotic breakpoint-mapping panels. *Am. J. Hum. Genet.*, 56: 484-499, 1995.
42. Carrozzo, R., and Ledbetter, D. H. Dinucleotide repeat polymorphism mapping to the critical region for lissencephaly (17p13.3). *Hum. Mol. Genet.*, 2: 615, 1993.
43. Buetow, K. H., Weber, J. L., Ludwigsen, S., Scherpbier-Heddema, T., Duyk, G. M., Sheffield, V. C., Wang, Z., and Murray, J. Integrated human genome-wide maps constructed using the CEPH reference panel. *Nature Genet.*, 6: 391-393, 1994.
44. Vogelstein, B., Fearon, E. R., and Kern, S. E. Allelotype of colorectal carcinomas. *Science* (Washington DC), 244: 217-221, 1989.
45. Kern, S. E., Fearon, E. R., Tersmette, K. W. F., Enterline, J. P., Leppert, M., Nakamura, Y., White, R., Vogelstein, B., and Hamilton, S. R. Allelic loss in colorectal carcinoma. *JAMA*, 261: 3099-3103, 1989.
46. Rogers, L. W. Carcinoma *in situ* (CIS). In: D. L. Page and T. J. Anderson (eds.). *Diagnostic Histopathology of the Breast*, Ch. 12, pp. 157-192. Edinburgh: Churchill Livingstone, 1987.
47. Cornelis, R. S., Devilee, P., van Vliet, M., Kuipers-Dijkshoorn, N., Kersenmaeker, A., Bardeol, A., Khan, P. M., and Cornelisse, C. Allele loss patterns target regions. *Oncogene*, 8: 781-785, 1993.
48. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Soderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J. D., Marks, J., Ballinger, D. G., Barrett, J. C., Skolnick, M. H., Kamb, A., and Wiseman, R. *BRCA1* mutations in primary breast and ovarian carcinomas. *Science* (Washington DC), 266: 120-122, 1994.
49. Leone, A., McBride, W., Weston, A., Wang, M., Anglard, P., Cropp, C., Goepel, J., Lidereau, R., Callahan, R., Linehan, M., Rees, R., Harris, C., Liotta, L., and Steeg, P. Somatic allelic deletion of *NM23* in human cancer. *Cancer Res.*, 51: 2490-2493, 1994.
50. Yaremko, M. L., Wasylyshyn, M. L., Paulus, K. L., Michelassi, F., and Westbrook, C. A. Deletion Mapping reveals two regions of chromosome 8 allele loss in colorectal carcinoma. *Genes Chromosomes & Cancer*, 10: 1-6, 1994.
51. Emi, M., Fujiwara, Y., Nakajima, T., Tsuchiya, E., Tsuda, H., Hirohashi, S., Maeda, Y., Tsuruta, K., Miyaki, M., and Nakamura, Y. Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. *Cancer Res.*, 52: 5368-5372, 1992.
52. Tavassoli, F. A. *Pathology of the Breast*, pp. 227-261. Norwalk, CT: Appleton and Lange, 1992.
53. Pallis, L., Skoog, L., Falkmer, U., Wilking, N., Rutquist, L. E., Auer, G., and Cedermark, B. The DNA profile of breast cancer *in situ*. *Eur. J. Surg. Oncol.*, 18: 108-111, 1992.
54. Meyer, J. S. Cell kinetics of histological variants of *in situ* breast carcinoma. *Breast Cancer Res. Treat.*, 7: 171-180, 1986.
55. Nagai, M. A., Pacheco, M. M., Brentani, M. M., Marques, L. A., Brentani, R. R., Ponder, B. A. J., and Mulligan, L. M. Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients. *Br. J. Cancer*, 69: 754-758, 1994.
56. Chen, L., Neubauer, A., Kurisu, W., Wafsdman, F. M., Ljung, B. M., Goodson, W., III, Goldman, E. S., Moore, D., Balazs, M., Liu, E., Mayall, B. H., and Smith, H. S. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. *Proc. Natl. Acad. Sci. USA*, 88: 3847-3851, 1991.
57. Liscia, D. S., Venesio, T., Diella, F., Cappa, B. A., Callahan, R., and Merlo, G. R. A locus on chromosome 17p13.3 associated with a high S-phase index is distinct from the *p53* gene in breast cancer. *Ann. NY Acad. Sci.*, 698: 120-125, 1993.
58. Klein, G., and Klein, E. Evolution of tumors and the impact of molecular oncology. *Nature (Lond.)*, 315: 190-195, 1985.

ALLELIC LOSS ON CHROMOSOME 8p OCCURS EARLY IN THE DEVELOPMENT OF BREAST CARCINOMA


Diane M. Radford, MD, FRCS(Edin), FACS,
Matthew S. Holt, Jon H. Ritter, MD,
Nancy J. Phillips, MD, Keri L. Fair, BA,
Katherine DeSchryver, MD, Marlys E. Schuh, MD, FACS,
and Helen R. Donis-Keller, PhD

MANY CHROMOSOMAL REGIONS harboring tumor suppressor genes are implicated in the cascade of genetic events that leads to invasive breast cancer.¹ Loss of activity of a tumor suppressor gene is revealed as loss of an allele in the tumor DNA when compared to matched normal control DNA. We have presented data previously that loss of heterozygosity (LOH) on 17p occurs in the preinvasive lesion ductal carcinoma in situ (DCIS)² and is therefore an early event in breast cancer progression. We have assayed samples of DCIS for LOH at other chromosomal loci, including 8p, to determine the sites of other putative tumor suppressor genes involved in breast cancer oncogenesis.

MATERIALS AND METHODS

Sixty-four cases of DCIS were microdissected from paraffin-embedded, archival material to remove the adjacent normal stroma. DNA was extracted and polymerase chain reaction (PCR) carried out as

From the Departments of Surgery and Pathology, Washington University, Department of Pathology, St. Louis University, West Central Pathologists, Inc., and Parkcrest Surgical Associates, St. Louis, MO. Supported by an American Cancer Society Career Development Award and the US Army Research and Development Command.



Chromosome 8 deletions observed in 15 DCIS tumors. DCIS samples are numbered at the top. Genetic markers are uniquely placed with odds of 1:1,000 and are listed in the order determined. The genetic map and distances are shown on the left of the figure. Cytogenetic localization is shown by tie bars. D8S166 and UT721 map to 8q. ● = no loss; ○ = LOH; ⊙ = noninformative. A vertical line on the right of the figure and horizontal lines within the figure show the smallest common region of deletion.

described previously.³ PCR products were separated on denaturing polyacrylamide DNA sequencing gels. Either uninvolved lymph node or white cell DNA was used as normal control. PCR was carried out using eight microsatellite markers that map to 8p and two markers that localize to the long arm of the chromosome. The order of the 8p microsatellites from telomere to centromere is D8S262, D8S277, D8S520, D8S265, D8S552, D8S261, LPL, NEFL.

RESULTS

Of 55 cases of DCIS for which the assays were informative, LOH on 8p was seen in 15 tumors (27.3%). In six tumors the deletion appeared to involve the whole short arm, whereas in the remainder a smaller deletion was seen. The smallest common region of deletion localizes to a 1.3-cM region at 8p22-23, between markers D8S520 and D8S265 (Fig).

CONCLUSIONS

Little is known about the chronology of genetic events leading to invasion. Our data suggest that LOH of loci on 8p occurs before the development of the invasive phenotype in the progression of breast cancer. At least one tumor suppressor gene in the 1.3-cM region identified at 8p23 is implicated.

REFERENCES

1. Devilee P, van Vliet M, van Sloun P, et al: Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. *Oncogene* 6:1705-1711, 1991
 2. Radford DM, Fair KL, Thompson AM, et al: Chromosomal regions implicated in the development of breast cancer. *Surg Forum* 44:502-504, 1993
 3. Radford DM, Fair K, Thompson AM, et al: Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. *Cancer Res* 53:2947-2950, 1993
-

CHROMOSOMAL REGIONS IMPLICATED IN THE DEVELOPMENT OF BREAST CANCER

Diane M. Radford, MD, FRCSEd, Keri L. Fair, BA,
Alastair M. Thompson, MD, FRCSEd, Jon H. Ritter, MD,
Matthew Holt, Samuel A. Wells, Jr, MD, FACS, and
Helen R. Donis-Keller, PhD

MULTIPLE CHROMOSOMAL REGIONS harboring tumor suppressor genes are implicated in the oncogenesis and progression of invasive carcinoma of the breast.¹ Loss of activity of suppressor genes, allowing tumor formation to occur, can be detected by loss of heterozygosity (LOH) of the tumor DNA compared to normal control DNA. To identify initiating events and investigate the chronology of genetic changes in the development of breast cancer, we assayed LOH in ductal carcinoma in situ of the breast (DCIS) mainly using polymerase chain reaction (PCR).

MATERIALS AND METHODS

Because contamination of tumor DNA by surrounding normal cells can interfere with the detection of LOH, we separated tumor from stroma by microdissection of archival tissue.¹ DNA was extracted and PCR carried out as previously described.¹ The microsatellite markers used, which map to chromosome 17, were 12G6 (D17S513), TP53CA (TP53), Mfd188 (D17S579), UT18, DL1, CHRNB1, Mfd15 (D17S250), and NM23. For four tumors Southern analysis was performed with restriction fragment length polymorphism (RFLP) markers PYNZ22 (D17S30), MCT35.1 (D17S31), and pBHp53 (TP53). PCR products were separated on denaturing polyacrylamide DNA sequencing gels.

RESULTS

The markers 12G6 (D17S513), TP53CA (TP53), Mfd188 (D17S579), UT18, and DL1 were ordered uniquely within a multipoint linkage map. CHRNB1 maps closely to TP53 with odds of 47:1. On the short arm of chromosome 17, the order from telomere to centromere is UT18-D17S30-DL1-D17S513-TP53-CHRNB1-D17S31. On the long arm, from telomere to centromere lie D17S250-D17S579 and NM23. A total of 45 tumors have been examined to date. Of 39 tumors informative for markers on the short arm, LOH is seen in 10 (26%). In two cases, the length of

From the Departments of Surgery and Pathology, Washington University Medical School, St. Louis, MO, the Department of Pathology, St. Louis University Hospital, the Department of Surgery, Edinburgh Royal Infirmary, Scotland, and the MRC Human Genetics Unit, Edinburgh, Scotland. Supported by a VA RAG grant and ACS grant 42048R.




Fig 1—Summary of chromosome 17 deletions observed from 45 DCIS samples. DCIS samples are indicated along the top of the figure. Genetic markers are listed in the order determined from the multipoint map. ● = No loss; ○ = LOH; ○ = noninformative.

deletion does not extend to the most telomeric marker (UT18). As shown in Figure 1, the smallest common region of deletion involves the TP53 and D17S513 loci. LOH has not been seen with any of the markers from the long arm.

CONCLUSIONS

Two tumor suppressor genes have been proposed to reside on 17p¹ and two on 17q.² One 17q locus is thought to include the hereditary early-onset breast cancer gene (BRCA1) to which D17S579 is closely linked.³ We have demonstrated significant LOH on 17p (26%) at loci near the p53 gene, which does not involve a telomeric locus in all cases. These data suggest that at least one locus on the short arm of chromosome 17 is involved early in the development of breast cancer, whereas inactivation of a gene or genes on 17q may be involved in later stages of progression to the invasive phenotype.

REFERENCES

1. Radford DM, Fair K, Thompson AM, et al: Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. *Cancer Res* (in press)
2. Cornelis RS, Devilee P, van Vliet M, et al: Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions. *Oncogene* 8:781-775, 1993
3. Hall JM, Griedman K, Guenther C, et al: Closing in on a breast cancer gene on chromosome 17q. *Am J Hum Genet* 50:1235-1242, 1992